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Dose verification is a critical component of adaptive radiotherapy, as it provides a
measurement of treatment delivery success. Based on the measured outcome, the
plan may be adapted to account for differences between the planned dose and the
delivered dose. Although placement of an EPID behind the patient during treatment
allows for exit dosimetry which may be used to reconstruct the delivered patient dose
via backprojection of the fluence, there have not been any studies examining the basic
assumption of backprojection-based dose verification: that deviations between the
expected and delivered exit fluences are totally caused by errors in the delivered
fluence, and not caused by patient geometry changes. In this dissertation, the validity
of this assumption is tested. Exit fluence deviations caused by machine fluence delivery
errors are measured as well as those caused by interfractional changes in the patient
anatomy. Dose reconstruction errors resulting from the backprojection assumption are
assessed. Correlations are examined between exit fluence deviations and patient dose
reconstruction deviations. Based on these correlations, a decision tree is proposed

xxviii
detailing when caution should be taken in performing dose reconstruction to achieve
delivery verification. Finally, a semi-automated dose verification tool is constructed for
both clinical and research purposes.

1. Introduction

When diagnosed with cancer, several treatment options are available to the patient
including surgery, chemotherapy, and radiation therapy. One type of radiotherapy,
external beam radiotherapy (EBRT), involves the use of a linear accelerator to produce
high energy radiation incident on the patient. A standard workflow for EBRT involves
imaging the patient with a computed tomography (CT) imager. The physician then
identifies the tumor and surrounding normal structures on the CT image and designs a
plan that will deliver a tumorcidal dose while minimizing damage to normal structures.
This external beam is delivered at several incident angles on the patient to focus dose
on the tumor. Also, to take advantage of the differing recovery rates of cancerous and
normal tissues, the dose is divided into multiple fractions that are delivered on different
days across the span of several weeks.
Simply designing an ideal treatment plan, however, is not sufficient; successful
delivery of the plan to the patient is equally critical. Therefore quality assurance (QA)
tests are performed on the plan on the linear accelerator without the patient present.
Treatment plan QA ensures both that the plan data is successfully transferred from the
planning computer to the treatment machine and that the delivered beams are within
acceptable tolerance of the planned beams.
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Reproducibility of dose delivery over the course of treatment, however, is
problematic due to interfractional variation in both patient geometry and the treatment
machine output. The treatment plan is optimized on a CT which is acquired several
days prior to treatment delivery. Not only is there inherent variation in the patient set-up
position for each fraction of delivery, but the internal geometry of the patient is also
constantly changing both inter- and intra-fractionally. These variations cause the
delivered patient dose to deviate from the planned dose. Furthermore, standard plan
designing assumes no variation in machine output, which is not the case; the beam
output and positioning involves inherent levels of uncertainty.
Patient positioning uncertainties can be reduced through image guided
radiotherapy (IGRT), in which imaging of the patient in the treatment position is used to
improve daily patient alignment. Based on time-of-treatment image acquisition, the
patient may be shifted in order to reduce deviations between the planned position and
treatment position. The radiotherapy is ―guided‖ by the imaging.
Treatment delivery may also be improved through a process termed imageguided adaptive radiotherapy (IGART), in which the treatment plan is adapted to
geometric patient changes throughout treatment delivery. IGART allows for adaptation
to a changing treatment geometry with the goal of achieving a dose distribution
(accumulated over the fractional deliveries) that more closely achieves the planned
outcome, compared to delivery of the initial planned treatment for every fraction. For
example, if the tumor shrinks as each fraction is delivered, the treatment may be
adapted by shrinking the incident beam sizes, thereby sparing dose to the surrounding
normal tissue.
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IGART necessitates feedback between the patient status during delivery and
during planning. IGART also has the potential to correct for deviations between
delivered and planned dose, but in order to do so, the delivered dose must be
measured. When this measurement is fed back to the planning system, radiation
therapy planning and delivery becomes a closed loop system. A judgment may be
made on how well the treatment was delivered, and whether or not the treatment should
be replanned to account for delivered dose deviations. Direct measurement of the
received patient dose (in vivo dosimetry) is not feasible; it would require dosimeters to
be implanted throughout the patient. Therefore, an indirect method of dose verification
is more realistic. This indirect measurement may be achieved with a dosimeter
measuring the patient exit fluence (the radiation that transmits through patient), which
includes primary incident radiation and the attenuation of the beam by the patient.
Based on deviations between expected and measured exit fluences, accuracy of the
delivered patient dose may be inferred.
Patient exit fluence measurements have been used in direct comparison with
expected fluence predictions for visual verification of treatment delivery (Talamonti,
Casati et al. 2006; van Zijtveld, Dirkx et al. 2006; Bailey, Kumaraswamy et al. 2012).
While the exit fluence comparison allows for treatment validation, it only provides limited
guidance when deviations are observed. Exit fluence measurements have also been
used to estimate the delivered patient dose via a technique called patient dose
reconstruction (Louwe, Damen et al. 2003; Steciw, Warkentin et al. 2005; Wendling,
Louwe et al. 2006; Louwe, Wendling et al. 2007; McDermott, Wendling et al. 2008;
Wendling, McDermott et al. 2009; Mans, Wendling et al. 2010). On the surface, this
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seems to provide direct verification of the dose received. It does so by backprojecting
the measured exit fluence through a presumed patient anatomy and estimating dose.
However, the exit fluence is a result of the incident fluence and the patient attenuation.
Backprojection implicitly assumes that the patient anatomy is unchanged and therefore,
measured exit fluence deviations are only due to deviations in the fluence incident on
the patient. Commercial products are being developed based on this backprojection
assumption of idealized anatomy.
This dissertation examines exit dosimetry by (a) directly isolating and quantifying
sources of exit fluence deviations and (b) assessing the dosimetric consequences of
attributing patient-caused exit fluence deviations to incident fluence deviations.
Repeated EPID measurements of test fields were used to evaluate the precision of
beam delivery. Exit fluence deviations resulting from patient changes were quantified
via computer simulation methods to ensure exact knowledge of the simulated patient
anatomies and machine output. Together, these quantifications assess the
assumptions of ―backprojection‖ exit fluence-based dose reconstruction. To assist in
this analysis, a semi-automated dose verification and comparison tool was created.
This tool is useful not only for this dissertation, but also for efficiency gains in clinical QA.
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2. Background and Significance

2.1.

Image Guided Adaptive Radiotherapy

Image guided adaptive radiotherapy (IGART) combines image guidance with adaptive
radiotherapy (ART). Image guidance not only improves patient positioning throughout
the treatment, but also has the potential to update the patient geometry. The updated
geometry may then be used for adaptive treatment planning or treatment re-optimization
in order to account for differences between the original planning geometry and the
updated geometry.
One of the first implementations of ART was proposed by Yan et al. (Yan, Vicini
et al. 1997) to account for patient-specific anatomy variability. During the first week of
treatment, a fan-beam CT (FBCT) of the patient was acquired each day. Based on the
measured distribution of patient geometries, a patient-specific margin was incorporated
into the replanned treatment, which was delivered starting in the second week of
treatment. Letourneau et al. (Letourneau, Wong et al. 2007) proposed an online IGART
system in which, for each treatment fraction, a cone beam CT (CBCT) of the patient
was acquired, critical volumes were defined, and treatment was replanned while the
patient was on the treatment couch. In this scenario, the only opportunity for delivery
QA is during treatment delivery.
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Another instance of IGART was developed at the University of California San
Francisco: dose-guided radiation therapy (DGRT) (Cheung, Aubry et al. 2009). This
scheme involves adaptation of the treatment plan by accounting for daily differences
between the dose-of-the-day and the planned dose. In their proposed method, while
the patient is on the treatment couch immediately prior to delivery, a megavoltage CT
(MVCT) of the patient is acquired. This MVCT is corrected for various artifacts
associated with MV imaging. Since the field of view of an MVCT is not as large as an
FBCT, any critical missing data from the MVCT reconstructed geometry is assumed
using knowledge of the patient geometry from the FBCT acquisition. Critical structures
are recontoured, and replanning takes place while the patient remains on the treatment
couch. Differences between the original planned dose distribution and the new,
adapted dose distribution can be visualized in the control room, and the adapted plan is
delivered to the patient. This system was tested on six head-and-neck (H/N) patients as
well as two prostate patients. While the DGRT-adapted plan didn‘t show improvement
in target coverage, there was improvement in sparing of the organs at risk surrounding
the target.
When IGART is implemented, treatment replanning may result in a change to the
delivered fluence. However, quality assurance (QA) of the delivered fluence is needed.
One method is exit fluence measurement and comparison with planned exit fluence.
This exit fluence comparison method is used in this work, while other methods are also
examined.
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2.2.

Dose Verification Using Portal Dosimetry

The device used to measure the exit fluence must be accurate and reproducible. An
electronic portal imaging device (EPID) provides both high resolution (0.4 mm x 0.4 mm)
and accurate, precise measurements. The dose-response of three commercially
available EPIDs (Siemens, Elekta, Varian) has been characterized (McDermott, Louwe
et al. 2004; Nijsten, van Elmpt et al. 2007). In this dissertation, Varian aS500 and
aS1000 EPIDs were used. Greer et al. (Greer and Popescu 2003) and Van Esch et al.
(Van Esch, Depuydt et al. 2004), found that dose response and dose-rate response
were approximately linear for a Varian aS500 EPID. Greer et al. also found that there
was a field-size response of -2% for a 4×4 cm2 field relative to a 10×10 cm2 field and a
+2.5% response for a 24×24 cm2 field relative to a 10×10 cm2 field with respect to
ionization chamber measurements in water. This field size response was caused by
backscattering from the EPID positional arm and has been reproduced though
simulations at our institution. Dosimetric differences due to field-size response are
accounted for through backscattering correction factors (Wang, Gardner et al. 2009).
Greer et al. also concluded that the buildup effect was insignificant for 6 MV beams.

2.2.1. Pretreatment Verification
For intensity modulated radiotherapy (IMRT), pretreatment delivery of the patient
radiation fields to a dosimeter is performed in order to validate transfer of the treatment
planning information from the treatment planning system (TPS) to the linac, as well as
the deliverability of the treatment (Ezzell, Burmeister et al. 2009). The accelerator
output fluence corresponding to each treatment field is measured without the patient in
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the field prior to treatment delivery. This fluence can be compared to the expected
fluence (Talamonti, Casati et al. 2006; van Zijtveld, Dirkx et al. 2006; Bailey,
Kumaraswamy et al. 2012) or used to estimate the patient dose distribution
corresponding to the delivered fluence in order to verify delivered and planned dose
distributions (van Elmpt, Nijsten et al. 2006; van Zijtveld, Dirkx et al. 2007; van Elmpt,
Nijsten et al. 2008).
The basic goal of pretreatment delivery is to ensure accurate patient treatment
dose delivery. The task group (TG) report on IMRT commissioning (Ezzell, Burmeister
et al. 2009) recommends that delivered dose be within 5% of planned dose in areas of
high dose and low gradient, and within 7% in areas of low dose and low gradient. Also,
90% of delivered dose points should agree within 3% and 3 mm with the expected dose
points. Pretreatment verification can detect delivery errors caused by transfer failure of
the treatment plan between the planning system and the delivery system. This failure
might result from human errors (e.g. selecting the wrong plan to transfer to the delivery
machine) or from system errors (e.g. network transmission). Pretreatment verification
can also catch errors caused by linac‘s inability to accurately deliver the planned
treatment. This failure potentially could be caused by variation in the accelerator output
or the physical limitations of the multileaf collimator (MLC). Either of these deviations
could be detected through use of pretreatment verification.
One shortcoming of pretreatment verification, however, is that the duringtreatment delivered dose is not verified. There is a critical assumption being made that
the treatment machine will reproduce the pretreatment fluence for each treatment.
Changes or errors introduced between pretreatment verification and treatment delivery
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will escape detection. Therefore during-treatment verification is necessary to validate
daily dose delivery.

2.2.1.1. Gamma Comparison Metric
Whether comparing two two-dimensional images, such as fluence maps, or two threedimensional images, such as patient dose maps, the standard comparison metric for
verification is the gamma metric (Low and Dempsey 2003). The gamma metric
combines both the dose difference between the same pixel in an evaluated and a
reference image as well as the distance-to-agreement (DTA) between the evaluated
image pixel and the closest pixel in the reference image that equals that value. The
user sets tolerances levels for both metrics—for example, a 3% dose difference
tolerance and a 3 mm DTA tolerance. The gamma value for each pixel is calculated
using the following formula:

where

is the spatial distance between the evaluated and reference dose points,
is the difference between the evaluated dose

dose

at position

,

is the DTA tolerance, and

at position

and reference

is the dose difference

tolerance. A pixel which fails either the DTA or dose difference tolerances will have a
gamma value greater than one. The per-pixel gamma results can be plotted so that
areas of failure are evident. TG Report 119 recommends that 90% of pixels pass the
gamma metric with tolerances of 3% and 3 mm (Ezzell, Burmeister et al. 2009).
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Naïve usage of the gamma metric, however, can lead to misleading results. MCgenerated images have abnormally high gamma pass rates since the inherent statistical
noise in the simulation yields lower DTAs between the evaluated and reference images.
Also, even though the gamma metric is generally accepted as the proper comparison
metric, there is poor correlation between gamma passing rates and delivery success
(Yan, Liu et al. 2009; Nelms, Zhen et al. 2011; Gordon, Gardner et al. 2012).

2.2.1.2. DPI Comparison
Pretreatment dosimetric portal image (DPI) validation entails comparison of measured
DPIs for each treatment beam with DPIs predicted based upon beam information in the
TPS. These expected DPIs can be directly predicted by some TPSs (such as Varian‘s
PortalVision software based on Van Esch et. al.) (Van Esch, Depuydt et al. 2004),
computed with external analytic programs (Van Esch, Vanstraelen et al. 2001), or
computed via Monte Carlo (MC) radiation transport simulations (Siebers, Kim et al.
2004; Parent, Seco et al. 2006). Differences between the actual and predicted fluences
ideally can be pinpointed to machine-related variations or treatment plan data transfer
failure. Subsequently, these errors can be corrected prior to actual patient treatment.
EPID-based pretreatment fluence verification has been performed at several
institutions (Talamonti, Casati et al. 2006; van Zijtveld, Dirkx et al. 2006). At the
University of Florence hospital, an aSi EPID was dosimetrically calibrated to match
TPS-generated doses over a range of field sizes for beam energy 6 MV. Comparisons
between measured and simulated fields for a series of fifteen clinical IMRT fields
resulted in an average of 97.6% of pixels passing gamma for criteria of 3% and 3 mm.
This agreement was comparable to that achieved when radiographic film was used to
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measure the delivered fluence. The EPID was preferred over film for pretreatment
verification, due to the greater time and effort required to use film (Talamonti, Casati et
al. 2006). Pretreatment verification using DPI comparison had been performed at the
Erasmus Cancer Center in Rotterdam for three years by 2006. In 270 patient treatment
courses, four clinically relevant errors were caught. One instance involved the wrong
plan transmitted to the treatment machine, while the other three involved MLC leaf
malfunctions (van Zijtveld, Dirkx et al. 2006).
As arc therapy has become more widespread over the past several years, EPIDbased pretreatment verification has been utilized in that modality as well. At the
Roswell Park Cancer Institute in Buffalo, two EPID dosimetry systems were compared
to a standard diode array for fourteen prostate arcs and twelve head and neck (H/N)
arcs. On average, both systems yielded 98% of pixels passing gamma (3%, 3 mm) for
the prostate cases, and 95% for the H/N cases (Bailey, Kumaraswamy et al. 2012).
One of the goals of this work is to provide our institution the framework for using
DPI-based pretreatment verification. Prior to 2009, in addition to independent MC
calculations, our clinic performed IMRT QA through visual inspection of differences
between the planned and measured DPIs. Afterwards, this qualitative method was
replaced by a quantitative one: using an I‘mRT Matrixx (IBA Dosimetry America,
Bartlett, TN) two-dimensional array of ionization chambers, and its accompanying
comparison software. This comparison outputs the frequency of pixels that pass
gamma (i.e. have gamma values less than one) with tolerance levels set to those
recommended in TG 119 (Ezzell, Burmeister et al. 2009). Since there are inherent
advantages to an EPID-based verification system, the goal is to revert back to that
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system, but with added improvements in automation and quantitative assessment
(discussed in section 5.1), notably improving upon the potentially misleading gamma
metric.

2.2.1.3. Patient Dose Reconstruction
As the true goal of QA processes is to ensure that treatment delivery will result in the
planned treatment dose, an enhancement of pretreatment verification is to use the
measured DPIs to reconstruct the delivered dose in a planning CT geometry. In this
case, instead of determining the success of the delivery based on deviations in the 2-D
DPI, a judgment may be made based on deviations between the original planned and
reconstructed 3-D patient dose. In a pretreatment context, EPID-based patient dose
reconstruction is achieved by backprojecting fluence (as measured by DPIs at the EPID
measurement plane) to the exit of the accelerator head, and then utilizing this fluence in
a forward calculation of the patient dose (van Elmpt, Nijsten et al. 2006; van Zijtveld,
Dirkx et al. 2007). Some current commercial pretreatment QA products (MapCHECK,
Sun Nuclear) use this method of verification.
At the University Hospital Maastricht, pretreatment patient dose reconstruction
was performed on nine 3D conformal lung plans and five IMRT H/N plans (van Elmpt et
al. 2008). Differences between the planned and reconstructed patient dose DVHs were
used for judgment of delivery success. Differences less than 5% were observed in the
mean PTV dose for the lung cases, while there were no significant differences in the
lung and spinal DVH parameters. For the H/N cases, differences in the mean PTV dose,
the mean parotid dose, and the maximum spinal cord dose were about 3%.
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In similar work, physicists at Erasmus iteratively estimated the incident fluence
required to produce the measured exit fluence, then utilized that fluence in a patient
dose calculation (van Zijtveld et al. 2007). Their method was demonstrated for ten
head-and-neck (H/N) cancer treatment plans and five rectum cases. Gamma analysis
(2%, 2 mm) showed agreement in more than 95% of voxels. Differences in DVH
parameters were less than 2%. Also, two of the cases which previously failed their
earlier DPI-comparison method were re-examined using patient dose reconstruction. In
the case of the MLC leaf malfunction, it was observed that DVH comparison resulted in
good agreement for the PTV dose. However, the gamma analysis showed local failure
in the PTV volume over which the malfunctioning MLC leaf was positioned. It was
concluded that simple DVH analysis of the reconstructed patient dose was not a
sufficient means to catch significant local errors; however, using a 3-D gamma analysis
would detect these errors.
Pretreatment patient dose reconstruction based on measured delivery fluences is
useful to detect deviations between dose distributions approved by the physician during
the treatment planning process. Similar to pretreatment fluence-based DPI
comparisons, pretreatment dose reconstruction inherently cannot detect unintended
alterations in the treatment delivery after pretreatment QA is performed. Furthermore,
as treatment planning transitions from a once- or twice-per-treatment process to a daily
online process, the ability to do pretreatment QA diminishes. When a treatment plan is
generated based upon a time-of-treatment image of the patient on the treatment
machine, it is neither practical nor desirable to move the patient for the purposes of
performing pretreatment QA.
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2.2.2. During Treatment Verification
As noted previously, shortcomings of pretreatment verification include its inability to
detect intentional changes in the treatment plan or unintentional changes in the delivery,
either via changes in the record and verify (R&V) database or equipment failures.
These changes, however, can be detected using during-treatment measurements. In
this scenario, the imager is extended behind the patient during treatment delivery, and a
through-patient image is acquired for each delivered beam. Instead of comparing the
planned dose to the expected dose, the planned dose may now be directly compared to
the predictions of the delivered dose. Although passive during-treatment QA may not
prevent delivery of deviant doses, it will detect deviant dose delivery and can enable
treatment delivery adaptations of future fractions to achieve the planned treatment.
Active during-treatment QA, which monitors exit fluence as it is being delivered
and compares it with expected fluence delivery, has the potential to prevent gross
treatment delivery errors (Mutanga, de Boer et al. 2012). Both determining treatment
adaptations and implementation of a closed-loop active delivery QA system are beyond
the scope of this work. This work‘s goal is to detect and classify delivery deviations
which would trigger plan adaptation.
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Figure 1: Flow chart for exit fluence-based delivery verification. For pretreatment verification, the DPI is simulated
without the patient geometry present in the beam. For during-treatment verification, the DPI is simulated through an
assumed patient geometry.

2.2.2.1. DPI Comparison
The information flow for during-treatment DPI acquisition is shown in Figure 1. Similar
to pretreatment verification, during-treatment verification can be accomplished via direct
comparison of DPIs or by patient dose reconstruction. Simulating during-treatment
DPIs requires an estimate of the fluence incident upon the patient as well as an
estimate of the patient geometry. The former can be obtained from the TPS or a
simulation of the beam delivery, while the latter can be obtained from the treatment
planning CT image or a more recent image of the patient anatomy, e.g. from a
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pretreatment image of the patient on the treatment machine. Using this input image,
simulated DPIs can be generated via analytic or MC methods (Kroonwijk, Pasma et al.
1998; Pasma, Heijmen et al. 1998; McCurdy and Pistorius 2000; McCurdy, Luchka et al.
2001). These simulated DPIs are then compared with the measured DPIs for each field
to determine if the treatment was delivered successfully.
Pasma et al.(Pasma, Heijmen et al. 1998) predicted DPIs by ray-tracing the
primary fluence through the patient CT and then adding a rotationally-symmetric scatter
kernel to account for scatter. McCurdy et al. (McCurdy and Pistorius 2000; McCurdy,
Luchka et al. 2001) predicted DPIs by ray-tracing the incident fluence through the
patient CT and then adding a MC-calculated scatter portion. Kroonwijk et al.(Kroonwijk,
Pasma et al. 1998) were able to detect the presence of air pockets in the rectum in
prostate cases due to differences between the simulated and measured DPIs. In all of
these studies, the expected exit fluence was calculated based on the patient geometry
obtained from the planning CT.
In this work, two different methods were used to simulate during-treatment DPIs:
1) MC simulation and 2) calculation of an attenuation-based primary component
combined with an estimate of a scatter component. While the former method should
provide accurate DPI estimates, it can be CPU intensive (time consuming). While the
accuracy of the latter method is less than that of MC simulation, I hypothesize that it will
still be sufficient to detect gross delivery errors.

2.2.2.2. Patient Dose Reconstruction
The measured DPI can also be used to reconstruct the patient dose (Louwe, Damen et
al. 2003; Steciw, Warkentin et al. 2005; Talamonti, Casati et al. 2006; Wendling, Louwe
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et al. 2006; McDermott, Wendling et al. 2008; Wendling, McDermott et al. 2009; Mans,
Wendling et al. 2010). Patient dose reconstruction is more prevalent than comparison
of expected and actual DPIs because it allows for dose verification of the threedimensional patient dose, whereas comparison of DPIs does not provide such a
straightforward understanding of delivered dose.

Figure 2: Flow chart for dose reconstruction-based delivery verification. To backproject the exit fluence for dose
reconstruction, the best estimate of the patient geometry is assumed. The reconstructed dose is then compared to
the planned dose.

Patient dose reconstruction requires backprojection of the measured fluence
through the patient geometry. A flow chart of this process is shown in Figure 2. A DPI
17

is acquired during treatment delivery. The exit fluence is obtained from the DPI by
deconvolving the image with kernels which were calculated to match simulated DPIs
with measured DPIs. At this point the exit fluence contains both the primary fluence
(which transmitted through the patient without interaction) and patient scatter.
Backprojection of the patient scatter is inappropriate because the source of each scatter
particle inside the patient is unknown.

Since an estimate of the patient scatter is

obtainable via MC simulation, this estimate may be subtracted from the exit fluence,
leaving the primary exit fluence. The primary fluence is then backprojected to achieve
dose reconstruction.
One method to reconstruct the dose involves backprojecting the primary fluence
through the patient back to its source in the accelerator head. The fluence is then
placed incident on the patient and used to calculate the patient dose in a forward
manner (Talamonti, Casati et al. 2006). Another method involves backprojecting the
primary fluence into the patient to reconstruct the primary dose. The fluence is then
convolved with an appropriate kernel to estimate the scatter component of the patient
dose (Wendling, Louwe et al. 2006).
One

of

the

leading

institutions

in

backprojection-based

patient

dose

reconstruction is the Netherlands Cancer Institute-Antoni van Leeuewnhoek Hospital
(NKI). In their system the measured DPI is backprojected to a plane through isocenter
inside the patient which is normal to the beam direction, while accounting for the
inverse-square law, beam attenuation, and scatter originating from the patient, the table,
and the EPID itself.

While single planar dose is not three-dimensional dose

reconstruction, the planned and reconstructed planar doses in the patient plane typically
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agree within 1% for IMRT fields (Wendling, Louwe et al. 2006). Updates to this method
include use of time-of-treatment cone beam CTs (CBCTs) (McDermott, Wendling et al.
2008), expanding dose estimation to 3D (Wendling, McDermott et al. 2009), and arc
therapy dose reconstruction (Mans, Wendling et al. 2010).

The NKI fluence

backprojection essentially reconstructs the dose distribution in the accelerator
coordinate system, thereby permitting comparison of the planned and delivered
planning target volume (PTV) dose distributions.
A base assumption of patient dose reconstruction is that the patient geometry is
equal to that assumed for dose reconstruction. Any changes to the patient geometry
between the time of imaging and the time of treatment delivery are ignored. During
patient dose delivery, the patient exit fluence is formed from 1) the fluence entering the
patient, 2) attenuation by the patient, and 3) scattered radiation from the patient. When
the exit fluence is backprojected through the patient geometry for dose reconstruction,
any differences between the expected and measured patient exit fluences are attributed
completely to deviations in the delivery of the fluence entering the patient independent
of whether such deviations are plausible or not.
In this dissertation, I hypothesize that differences between expected and
measured patient exit fluences are not completely due to deviations in the fluence
incident on the patient. Specifically, this work quantifies fluence delivery errors and
analyzes exit fluence deviations caused by changes in the patient geometry.
Furthermore, I conjecture that exit fluence deviations are primarily caused by variations
in patient anatomy, and therefore, caution should be used when relying on patient dose
reconstruction to achieve delivery verification.
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2.2.3. EPID-based Verification Tools
A potentially significant increase in workload for clinicians is required if each measured
and expected DPI must be compared visually and presence of any significant
differences determined. To avoid the extra time required for comparison, some semiautomatic comparison tools have been implemented which sort out any cases where
there are clearly no significant differences between the DPIs (van Zijtveld, Dirkx et al.
2006; Mans, Wendling et al. 2010).
Van Zijtveld et al. (van Zijtveld, Dirkx et al. 2006) implemented a pretreatment
fluence verification system in which visual inspection of the DPIs was avoided in twothirds of the cases for 270 patients. For automatic approval, each field had to pass
three tests:
The percentage of pixels failing gamma (3% / 3 mm) had to be less than 15%.
The largest area of gamma failure had to be less than 5 cm 2.
If failure areas larger than 1 cm2 existed, each area had to have an average
gamma less than 1.5 and a maximum gamma less than 2.
If a field failed any of these criteria, then it was flagged for manual review. Their semiautomatic comparison tool was able to catch four cases in which the differences were
clinically significant: in three cases a MLC leaf was malfunctioning, and in the fourth
case the incorrect patient plan was loaded. The comparison metric they based their
decisions on was the gamma index.
Both pretreatment and during-treatment verification systems have been in place
at the NKI since 2005. From 2005 to 2009, of the 4337 patient treatment plans verified,
seventeen major plan deviations were detected, including deviations caused by patient
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anatomy changes (six), transmission failure between the TPS and treatment machine
(four), suboptimal tuning of the treatment plan (two), accidental modification of the
record-and-verify system immediately prior to treatment delivery (two), an undeliverable
plan (one), and the treatment machine skipping a segment of an IMRT delivery (one).
Together, these systems show the positive potential of EPID-based treatment
verification.
In this dissertation, a semi-automatic comparison tool was created for
pretreatment and during-treatment fluence validation. In addition to the gamma metric
employed by others, comparison metrics based on dose differences were used. While
the DTA component of the gamma metric is useful for accounting for EPID positioning
errors, it is also capable of producing false positives and negatives in the presence of
fluence deviations caused by changes in the patient anatomy. The developed tool can
alert the user when differences between the planned and delivered exit fluences are
significant, thereby ―closing the loop‖ of radiation therapy treatment delivery.

2.3.

Hypothesis and Goals

The overriding goal of my dissertation is to develop a clinically viable treatment dose
validation system utilizing EPID-based fluence verification. In pursuit of this goal, the
base assumptions of dose reconstruction were tested. The sizes of fluence deviations
caused by the treatment accelerator were experimentally quantified to test the
plausibility of attributing measured exit fluence deviations to changes in the input
fluence. The impacts of changing patient anatomies on exit fluence were quantified by
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developing a Monte Carlo simulation framework which permitted dose computation on
multiple patient anatomies both with and without back-projection based fluence
adjustments.
In this work it was hypothesized that patient anatomical variations, as opposed to
variations in the fluence produced by the accelerator, have a greater likelihood to alter
exit fluences. It was hypothesized that dose reconstruction can be erroneous if it is
falsely assumed that all exit fluence deviations are caused by machine-related entrance
fluence deviations. Furthermore, it was surmised that comparison of predicted and
measured exit fluences would be a sufficient means of dose verification, while
comparison of planned and reconstructed patient doses should only be performed when
minimal exit fluence deviations exist. A QA flow chart was formed to determine when
fluence-based or patient dose-based verification should be implemented. To permit
implementation of EPID-based QA, a semi-automatic tool was developed to aid
treatment delivery verification by comparing the expected and measured exiting
fluences.
Comparison of machine- and patient-related sources of exit fluence deviations is
covered in section 3 of this work. Examination of delivery verification errors caused by
reliance on the backprojection assumption required by patient dose reconstruction is
made in section 4. Design and function of the semi-automatic verification tool is
reported in section 5. Final discussion and conclusions appear in section 6.
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3. Sources of Exit Fluence Deviations

As previously mentioned, during-treatment exit fluence deviations from expected can be
caused by changes in the incident fluence or changes in the patient attenuation. While
dose backprojection inherently assumes the former, the frequency and plausibility of
this assumption has not been confirmed. As a goal of this dissertation is to separate
delivery machine related and patient attenuation related sources of exit fluence
deviations, this chapter examines these two sources.
Separate experiments were set up to isolate and estimate the machine-related
and patient-related sources of exit fluence variability. Machine-related sources were
quantified via repeated measurements of fluence delivery without a patient or phantom
in the beam. This material is described briefly in Section 3.1 with details published in
Physics, Medicine, and Biology (Gardner, Clews et al. 2009) as well as presented at the
Electronic Portal Imaging International Workshop in 2008. The journal article is shown
in Appendix I. Quantification of patient-related sources of exit fluence deviations
required decoupling of the patient-related sources from machine-related sources. To
accomplish this, MC radiation transport simulations were employed. In the simulation
environment, the entrance fluence could be exactly replicated and placed incident on a
series of CT images for a given patient. Therefore all calculated exit fluence deviations
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could be attributed to changes in the patient geometry and not to changes in entrance
fluence or imager fluctuation. Details of the MC system are given in Section 3.2.1.

3.1.

Fluence Variation Caused by Machine-related Variability

The goal of this study was to quantify machine-related source of DPI variability.
Machine-related sources of DPI variability were separated into two broad categories: 1)
those related to the generation of the incident beam, and 2) those related to
measurement fluctuations inherent in the detection system. Incident fluence sources
include linac output fluctuation as well as positioning variance of the linac head
components including MLC positions during IMRT delivery. Measurement sources
include EPID pixel calibration variations and detector positioning variations.
Measurements were acquired at beam accelerating potentials of 6 MV and
18 MV of the following fields:
Calibration flood and dark fields
Full-imager field
10×10 cm2 field
Picket fence field, which formed 1 mm-wide regions of high intensity every 3 cm
Complex prostate dynamic MLC IMRT field
Over the span of two months, sixty images were acquired of each field. The reader is
encouraged to review Appendix I for the remaining details of the experimental setup.
Results will be repeated here briefly.
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Figure 3: Dependence of averaged central axis area on averaged size and shape for flood fields. Circular areas of
different diameters are shown in the left plot and square areas of different side lengths are shown in the right plot.
Maximum variation is less than 0.2%.

The calibration variability of the EPID was found to be independent of the size or
shape of the averaged central axis area from 1 cm2 to 400 cm2 (Figure 3). The relative
daily outputs as measured by the average of the central axis area are seen in Figure 4
and Figure 5. The standard deviations (SDs) of the central axis area of the calibration
flood fields, shown in Figure 6 and Figure 7, were 3.0% and 1.9% for the 6MV and 18
MV accelerating potentials, respectively. These SDs correspond to the combination of
accelerator output variation and EPID detection variation. The SDs in the central axis
area of the flood field images, which were corrected for daily output variations by daily
dark/flood field calibration applied, were 0.2% for both accelerating potentials.
Calibrating measured images to daily-acquired calibration fields effectively eliminates
fluence variability due to accelerator output variation and EPID response variation.
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Figure 4: Relative daily output, as measured by the average of the central axis area of flood field images for a 6 MV
accelerating potential. The blue circles correspond to the calibration flood fields, while the red circles correspond to
the flood field images, which were normalized to the calibration flood fields.

By acquiring repeated measurements of the fields while adjusting the jaws
between measurements, I found that the uncertainty in the jaws positioning was less
than 0.2 mm (1 SD) at isocenter for each jaw. This uncertainty is less than half the size
of an aS1000 pixel. The maximum pixel SD caused by the jaws positioning uncertainty
was 2.3%. The pixel SD image is shown in Figure 8.
Repeated measurements while repositioning the EPID between measurements
showed that the measured uncertainty in the EPID positioning was also less than half of
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a pixel at isocenter. The EPID positioning variation caused a maximum fluence pixel
SD of 1.3%, as seen in Figure 9.

Figure 5: Relative daily output, as measured by the average of the central axis area of flood field images for a 18 MV
accelerating potential. The blue circles correspond to the calibration flood fields, while the red circles correspond to
the flood field images, which were normalized to the calibration flood fields.
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Figure 6: Standard deviation (SD) maps for the 6 MV calibration flood field (top left) and flood field image (bottom
left), along with corresponding histograms of the SD values.

28

pixel number

Pixel SD

pixel number

pixel number

pixel number

Pixel SD

Figure 7: Standard deviation (SD) maps for the 18 MV calibration flood field (top left) and flood field image (bottom
left), along with corresponding histograms of the SD values.
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Pixel number

Pixel SD

Pixel number

Figure 8: Fluence variability caused by uncertainty in jaws positioning. The intensity represents the standard
2
deviation (SD) of each pixel over 100 images, between which the jaws were moved to form a 20×20 cm field and
2
then moved back to the original 10×10 cm field. The maximum fluence uncertainty (1 SD) at the field edge was
2.3%. The x-jaws are located on the right and left edges, while the y-jaws are located on the top and bottom edges.
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Pixel number
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Pixel number

Figure 9: Fluence variability caused by uncertainty in EPID positioning. The intensity represents the standard
deviation (SD) of each pixel over 100 images, between which the imager was retracted and re-extended. The
maximum fluence uncertainty (1 SD) at the field edge was 1.3%.
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Figure 10: Patient test field is shown in the top row, while the picket fence MLC test field is shown in the bottom row.
The first column shows the fields themselves, while the second column shows the pixel standard deviations
(calculated over 60 images) in the inset with the histogram of the pixel SDs outside. The inset of the third column
shows the largest difference between any two images over the 60 images, along with the corresponding histogram of
the differences on the outside.

Images of a 6 MV picket-fence test field and a patient test field are seen in Figure
10, along with their corresponding pixel SD images and the largest difference image
between any two measured fields. The largest calculated pixel SD for the picket-fence
fields were 2.1% and 2.3% for the 6 MV and 18 MV accelerating potentials,
respectively. The largest calculated pixel SD for the patient fields were 1.0% and 1.1%
for the 6 MV and 18 MV fields, respectively. The largest percent difference between
any two picket-fence fields was 9.8% (6 MV) and 8.4% (18 MV). The largest percent
difference between any two patient fields was 4.2% (6 MV) and 3.5% (18 MV).
In addition to comparing raw images, images were compared after registration
and normalization. Inclusion of this preprocessing reduced the pixel SDs of the picketfence field to 1.6% (6 MV) and 1.8 % (18 MV), and the patient field to 0.8% (6 MV) and
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0.9% (18 MV). These results are summarized in Table 1. Utilizing registration and
normalization therefore improves the detectability of exit fluence deviations (Gordon,
Gardner et al. 2012).
Table 1: Maximum pixel standard deviations (over 60 images) and percent differences (between any two images) for
the picket-fence MLC test field and a patient test field for beam accelerating potentials of 6 MV and 18 MV, both with
and without rigid registration and output normalization.

Picket fence

Patient field

Maximum percent
difference (%)

Maximum
pixel SD (%)

6 MV

9.8

2.1

Maximum pixel SD (%) with
rigid registration and output
normalization
1.6

18 MV

8.4

2.3

1.8

6 MV

4.2

1.0

0.8

18 MV

3.5

1.1

0.9

The purpose of this study was to measure the fluence variation caused by
machine-related sources, so that the basic assumption of backprojection-based dose
reconstruction could be tested: that patient-related sources of fluence variation are
negligible compared to machine-related sources. Based on these results, fluence
variation caused by machine-related sources is expected to be 1% on average and no
greater than 5% in worst-case scenarios while the machine is still operating under
tolerances. Gross delivery errors could still happen due to machine-related failures, but
these will easily be characterized as machine errors, not variability.

3.2.

Fluence Variation Caused by Patient-related Variability

As mentioned, the other possible source of exit fluence deviations is from changes in
the patient attenuation and scatter due to variations in the patient anatomy. To
investigate this source, a study was designed to quantify exit fluence variability caused
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by changes in the patient geometry. I utilized our in-house MC system and coded in
additional functions as needed. This system is described in the following section.

3.2.1. Monte Carlo System
The MC system used at our institution gives the user options regarding fluence
generation, particle transport through the MLC, patient dose calculation, and DPI
generation. The incident fluence may be generated either by a phase space file
representative of a full accelerator head simulation or from a source model (Fix,
Stampanoni et al. 2001) that has been tuned to match our treatment machine. For
IMRT beams, particles are transported through the MLC using Siebers‘s method
(Siebers, Keall et al. 2002). Several patient dose calculation codes are coded into the
system, including MCNP (Pacilio, Aragno et al. 2007), DOSXYZnrc (Walters, Kawrakow
et al. 2005), and VMC++ (Kawrakow 2001). After transport through the patient, the exit
fluence is translated to the EPID location and a DPI is formed either using full MC
simulation (Siebers, Kim et al. 2004) or via convolution with energy-dependent kernels
(Wang, Gardner et al. 2009). For the studies in this dissertation, the Fix source model
was used as well as Siebers‘s MLC transport to generate the fluence incident on the
patient. Since VMC++ dose calculations have been validate against DOSXYZnrc at our
institution (Gardner, Siebers et al. 2007; Gardner, Siebers et al. 2007), VMC++ was
used for patient dose calculation and formation of the exit fluence. The DPI was then
formed via convolution of the fluence with energy-binned kernels.
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Figure 11: Basic setup of our in-house MC system (on left), and the additions I made to it (on right).

There were several additions I made to the library of codes, shown in Figure 11.
I adapted the source model to allow for a simple point source (discussed in Section
4.3.1) as well as a backprojected source (discussed in Section 4.1.3). I also added in a
particle handler which was useful for separation of the exit fluence into primary and
scatter components. Within the particle handler, upon being sourced, the direction and
energy of each particle in the incident fluence was stored in random access memory.
After transport through the patient/phantom geometry, the direction and energy of each
exit particle was compared to the stored values of the incident particle. If they agreed to
within roundoff error, the particle was labeled a primary particle; if not, it was labeled a
scatter particle. For patient dose calculation, I scripted in the ability for the dose grid
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resolution to be automatically set to the CT voxel resolution. I found that this increase in
resolution did not significantly affect the DPI calculation time, since per-pixel DPI
uncertainty decreases at a slower rate than per-voxel patient dose uncertainty.
Originally, the exit image (i.e. the convolved fluence) was the only output allowed. I
added the ability to score the fluence at the imager plane. The fluence and DPI could
now also be divided into primary and scatter fluences and images. Finally, I added
calculation of the uncertainty for both fluences and DPIs.

3.2.2. Monte Carlo Calculations
To examine the effect that changes in patient geometry have on the exit fluence, MC
calculations were performed with identical source particles to ensure that no fluence
deviations could be attributable to incident fluence variations. The patient cohort used
in this study was a dataset obtained from the NKI, which included nineteen prostate
patients. Each patient had from nine to fourteen FBCT acquisitions, which were
acquired throughout the course of treatment delivery. The CTs were rigidly registered
to each other using bony anatomy landmarks using an in-house algorithm (Fatyga,
Sleeman et al. 2012). The first FBCT of each patient was treated as the planning CT,
and plans were optimized on this geometry using the RTOG-0126 protocol (see
planning objectives in Table 2). A summary of the beam energy for each patient, as
well as the number of non-planning geometries is shown in Table 3. In ten patients, the
plans were optimized with beam energy of 6 MV. The remaining nine patients had
plans optimized with 18 MV beam energy. All plans included seven beams at beam
angles of 30º, 80º, 130º, 180º, 230º, 280º, and 330º. The GTV, rectum, and bladder
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were manually contoured on each patient image by a single physician. Since this
database only involves the prostate site, the GTV was representative of the CTV.
Table 2: Optimization objectives for the RTOG-0126 protocol. A 0.5 cm margin was added around each structure for
optimization. The objectives are listed according to weight.

ROI

Constraint Type

Target Dose (cGy)

% Volume

Weight

CTV + 0.5 cm

Min DVH

7920

98

100

CTV + 0.5 cm

Max DVH

8470

2

90

Rectum + 0.5 cm

Max DVH

6000

50

80

Rectum + 0.5 cm

Max DVH

6500

35

80

Rectum + 0.5 cm

Max DVH

7000

25

80

Rectum + 0.5 cm

Max DVH

7500

15

80

Rectum + 0.5 cm

Max Dose

8470

Bladder + 0.5 cm

Max DVH

6500

50

80

Bladder + 0.5 cm

Max DVH

7000

35

80

Bladder + 0.5 cm

Max DVH

7500

25

80

Bladder + 0.5 cm

Max DVH

8000

15

80

Bladder + 0.5 cm

Max Dose

8470

L Femur + 0.5 cm

Max DVH

3500

L Femur + 0.5 cm

Max Dose

5000

R Femur + 0.5 cm

Max DVH

3500

R Femur + 0.5 cm

Max Dose

5000

80

80
50

20
20

50

20
20

Please note that, whereas my journal article detailed a single patient case, this
dissertation work has expanded to a greater number of patients. Also, the treatment
plan detailed in the article differed in that the pelvic nodes were also included in the
optimization process. This led to larger fields, with greater complexity and higher
intensity gradients. All seven beams were split into two separate fields. The plan was
optimized with 18 MV energy beams.
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For each patient, the exit fluence was simulated through each of the patient
geometries. For each patient geometry, each beam sampled the exact same particles
from the source model by using the same random seeds for source model input.
Therefore, all differences in the DPIs could be attributable to patient anatomy changes
and not to entrance fluence deviations. For each DPI, 2.5×107 particles were sampled,
yielding an approximate DPI statistical precision of one percent. Average total
calculation time per beam was approximately 25 minutes (distributed over ten
processors). Differences were computed between the simulated DPIs generated
through each of the patient CTs. The DPI per-pixel SDs (calculated over n patient
geometries) were also computed for each beam for each patient.
Table 3: Description of NKI patient database. It included nineteen total prostate cases, ten of which were optimized
with 6 MV beam energy. Not counting the first geometry, which was assumed to be the planning geometry, each
patient had several more day-of-treatment fan beam CTs.

1

Beam
energy
6 MV

Number of
geometries
11

11

Beam
energy
18 MV

Number of
geometries
11

2

6 MV

12

12

18 MV

13

3

6 MV

11

13

18 MV

10

4

18 MV

10

14

18 MV

10

5

6 MV

12

15

18 MV

12

6

6 MV

8

16

6 MV

12

7

18 MV

11

17

18 MV

12

8

6 MV

12

18

6 MV

11

9

6 MV

11

19

18 MV

10

10

6 MV

10

Patient

Patient
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For the published study, a sample patient beam is shown in Figure 12, along with
its corresponding pixel SDs (calculated over images from twelve patient geometries)
and largest percent difference between two DPIs. Per-pixel percent differences greater
than 5% (with respect to maximum intensity) existed in 16 out of 154 simulated DPIs for
this patient. The largest calculated pixel SD was 2.5%, and the largest pixel percent
difference between any two fields was 8.6%. Visual inspection of the patient CT data
showed that the primary sources of exit fluence deviations were changes in the patient
anatomy that resulted in different radiological pathlengths through the patient for the
source particles. In some cases, this change in attenuation was caused by changes in
the rectal filling. When gas was present in the rectum, the intensity of the DPI increased
behind the rectum. In other cases, particularly in beams at gantry angles of 80º and
280º, the edges of the beams became tangential with the patient‘s outer skin contour.
Therefore, slight changes in the height of the patient‘s abdomen on the treatment table
resulted in significant changes in beam attenuation length.

Figure 12: Patient-geometry-related sources of fluence variability. Panel (a) shows the exit fluence intensity for a
beam simulated through the planning geometry. Panels (b) and (c) show the histogram of the pixel SDs and the pixel
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SD image for this beam simulated through twelve different patient geometries-of-the-day. Panels (d) and (e) show
the histogram and image of the largest percent difference between any two DPIs simulated on any two given patient
geometries. The deviations present on the left side of the field were caused by the presence or lack of gas in the
rectum in each patient geometry. The deviations on the right side of the field were caused by deviations in the patient
contour on different patient geometries.

Results are show in Table 4 for the nineteen plans in which pelvic nodes were
not included in the treatment plan. Per-pixel differences greater than 5% existed in 935
out of 1,442 simulated DPIs (64% of fields), and greater than 10% existed in 384 fields
(26% of fields). Maximum per-pixel SDs for each patient ranged from 1.8% to 12.7%.
Differences were most pronounced in patients whose planning CT contained a large
amount of rectal gas.

Table 4: DPI variation caused by changes in the patient anatomy between the planning geometry and the day-oftreatment geometry. All differences were calculated with respect to maximum dose in the planning DPI.

1

Maximum
difference (%)
26.0

Maximum
SD (%)
7.5

2

36.9

12.7

Patient

11

Maximum
difference (%)
8.4

Maximum
SD (%)
3.1

12

14.4

5.7

13

10.4

4.2

Patient

3
4

14.0

5.4

14

6.0

1.8

5

12.6

4.2

15

8.1

2.2

6

17.7

6.3

16

15.7

6.1

7

10.5

4.2

17

8

15.2

4.1

18

21.9

8.3

9

18.8

8.0

19

8.1

3.4

10

20.6

6.2
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3.3.

Comparison of Sources of DPI Deviations

While machine-related sources of fluence variation resulted in maximum DPI pixel SDs
of 1% and maximum deviations of 5%, patient anatomy-related sources resulted in
maximum DPI pixel SDs over 12% and maximum deviations of 36%. Exit fluence
deviations caused by patient-geometry-related sources were greater than those caused
by machine-related sources, within the limits of this study. Tests with our delivery
system indicate that per-delivery fluence variations caused by machine-related sources
of variation are within the acceptable tolerances expected for patient treatment. For our
system, blind application of the backprojection assumption to determine the incident
fluence for patient dose reconstruction is not justified. Doing so would likely attribute
patient-geometry-related sources of exit fluence deviations to incident fluence
deviations—the wrong source.
It should be noted, however, that gross delivery errors could happen as a result
of machine failure, such as failure of plan transfer to the treatment machine or failure of
MLC leafs to remain in tolerance. Even though these gross delivery errors would
exceed the deviations caused by patient anatomy variations, they would easily be
characterized as machine-related errors due to the size and shape of the DPI deviation
maps. In cases where gross delivery occur due to machine failure, backprojectionbased dose reconstruction can be performed since the exit deviations are caused by the
entrance deviations (as long as concurrent deviations caused by patient anatomy
variations are insignificant in comparison).
This work was limited to a prospective study of detecting and measuring exit
fluence deviations. Therefore, several other potential machine-related sources of
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fluence variability have perhaps gone unmeasured. These sources include variability
caused by gantry and collimator angle variation. For pretreatment verification these
sources have not caused any problems in the past, since all measurements were
acquired at gantry and collimator angles of zero degrees. However, for through-patient
verification, possible gantry sag and collimator rotation must be accounted for.
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4. Exit Dosimetry for Closing the Loop of Image Guided Adaptive
Radiotherapy

―Closing the loop‖ of IGART refers to feeding back information from treatment delivery
verification for purposes of affecting future deliveries. The two basic methods studied in
this work which yield delivery verification are comparison of simulated and measured
DPIs, and comparison of planned and actual patient doses. In this chapter, correlations
between DPI deviations and patient dose deviations will be examined, and
recommendations will be made as how dose verification should be performed.

4.1.

Patient Dose Deviation Simulations

An intuitive means of patient dose delivery verification involves comparison of planned
and delivered 3D patient dose maps and DVHs. Direct patient dose comparisons
circumvent challenges associated with correlating DPI deviations to patient dose
deviations. In this section, a method to reconstruct the patient dose is described, as
well as its assumptions and limitations. Correlation between DPI deviations and patient
dose deviations is also examined.

4.1.1. Planned Dose – Planning Geometry
Standard treatment delivery involves 1) acquisition of a planning CT, 2) plan
optimization on the planning CT to some predetermined objectives, and 3) subsequent
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delivery of this plan to the patient for all fractions. Between 2) and 3), beam parameters
are transferred to the treatment machine‘s R&V system to ensure that planned beams
are delivered throughout the treatment course. The total planned dose to the patient is
divided into a fractionation scheme to favor normal tissue sparing, and the summation of
the fractional doses is assumed to equal the delivered dose. Throughout delivery, it is
assumed that changes in the patient geometry negligibly affect the dose delivered to the
patient. Setup uncertainties and patient geometric changes are ideally absorbed by
margins placed around the target and other structures of interest. This planned dose to
the planning target volume (PTV) is said to be representative of the dose received by
the patient‘s clinical target volume (CTV).
To simulate the offsets of differing fractional patient poses, the nineteen patient
NKI prostate database was utilized (a description of the database was given in Section
3.2.2). For this study, each acquired CT was treated as a separate ―fraction‖ of delivery.
Each fraction was given equal weighting, and the delivered dose to each patient pose
was calculated by:

where D is the dose,

P

is the planning-geometry-optimized fluence incident on the

fractional geometry GF, and nf is the number of fractional geometries obtained for the
patient. Note that the dose was not accumulated over all fractions, but instead each
fraction was viewed as representative of a total treatment dose by multiplying it by the
number of fractions. For the planned dose, since the patient geometry is assumed to be
unchanged, the dose was calculated on the planning CT, and then multiplied by nf as
well.
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The treatment plans were optimized to the high dose arm of the RTOG-0126
protocol. The optimization objectives are shown in Table 2. The quality of plan
optimization should have little effect on the comparisons made among the different
patient poses, since each patient pose used the same plan which was optimized on the
planning geometry.

4.1.2. Delivered Dose – Time-of-Treatment Geometry
As shown in chapter 3, the variation in patient geometry over the course of treatment
delivery yields non-negligible changes in the exit fluence. To determine the effect of the
anatomic changes on the delivered dose, the dose for each image set was computed by
impinging the same source particles from the fluence (optimized on the first CT) on
each fraction‘s CT. This was possible with the MC dose calculation system by ensuring
that the same random seeds were set for each component of the simulation for each
fractional delivery. Using this correlated source model assured that all observed dose
differences were caused by differences in the patient‘s anatomy. These fractional
doses were termed the true doses, as they reflected our best estimate of the delivered
dose to the patient. For each fraction, the true doses were then compared to the
planned dose. Differences between planned and delivered doses were caused by the
patient geometry variation throughout the treatment course. Results of this comparison
will be shown after the next section as these doses are also compared with
backprojected doses as described below.
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4.1.3. Reconstructed Dose – Planning Geometry
As shown in Section 3.3, dose delivery through a patient geometry that differs from the
geometry used to predict the time-of-treatment DPI will result in differences between
measured and predicted DPIs. Even though for this in silico study, identical incident
fluences were incident upon the differing daily poses, clinically, when deviations
between predicted and measured DPIs are observed, several groups backproject the
exit fluence through the patient geometry to estimate the patient dose (Steciw,
Warkentin et al. 2005; Talamonti, Casati et al. 2006; Mans, Wendling et al. 2010). To
quantify the dose as predicted by backprojection, the following procedure was followed.
The exit fluence corresponding with the planning geometry was calculated
through the first acquired CT for each patient, as was the exit fluence through each
fraction‘s geometry, termed the actual exit fluence. The backprojection-based
reconstructed patient dose was obtained in similar fashion to the true dose, except the
incident fluence was multiplied by the ratio of the true exit fluence to the planned exit
fluence:

where DR is the reconstructed dose,
planning geometry,
and

P

is the optimized fluence incident on GP, the

is the exit fluence calculated through each fraction‘s geometry,

is the exit fluence calculated through the planning geometry. The reconstructed

dose was then compared to the true dose.
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Figure 13: Demonstration of how the backprojection assumption could lead to erroneous dose reconstruction. A
planning target (red circle) is located inside a water phantom. The planning fluence is incident on both the planning
phantom geometry (left) and treatment phantom geometry (center). An air gap which was not present in the planning
geometry, has been introduced in the treatment geometry. Due to less attenuation in the treatment geometry, the
measured DPI has an area of higher intensity when compared to the expected DPI (estimated using the planning
geometry). In the backprojection assumption, the DPI deviation is attributed to the incident fluence. Dose
reconstruction will result in a higher estimated target dose, while the reconstructed DPI will agree with the measured
DPI.

It was hypothesized that, for patient cases, deviations between the reconstructed
and true doses would be larger than deviations between the planning and true doses.
The reasoning for this hypothesis is shown in the following thought experiment (shown
in Figure 13). Consider the planning geometry to be a solid water phantom, and the
time-of-treatment geometry to be the same solid water phantom, except with a volume
of air in the beam-line. The CTV is located directly in front of where the air pocket
exists. The time-of-treatment measured exit fluence would be equal to the expected
exit fluence except for the area directly behind the air pocket, which would have a
higher intensity due to a lower attenuation pathlength through the air pocket. For
backprojection-based patient dose reconstruction, this deviation would be attributed
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wrongfully to deviations in the incident fluence, which would be assumed to have an
area of higher intensity. The reconstructed patient dose uses an incident fluence with
an area of higher intensity, and therefore the reconstructed dose would be elevated
throughout the patient along the area covered by the higher intensity area. While both
the reconstructed and true doses for the CTV are higher than the planned CTV dose,
the reconstructed dose also has higher dose in all normal structures along the beam as
well. While this is a simplified thought experiment, it indicates that caution must be
exercised before blindly using fluence backprojection to achieve dose reconstruction.

4.1.4. Planned, Actual, and Backprojected Dose Comparisons
A simple metric to compare patient plans is the dose-volume histogram (DVH). Indeed,
DVH metrics are used as a basis for both plan optimization and plan approval. DVHs
for the GTV, rectum and bladder for each patient are shown in Figure 34-82 in Appendix
II. Respective zoomed-in GTV DVHs are shown are also shown in Appendix II. Each
plot includes the planning DVH as well as each day-of-treatment delivered and
reconstructed DVHs. Histograms of several GTV dose indices differences are shown in
Appendix II also.
An example of a patient which showed minor deviations is patient 7 (Figure 5255). The average reconstructed GTV D95 is 2 cGy less than the planned D95, while the
average actual D95 is 38 cGy less than the planned. If the plan were to be adapted to
achieve the same exit fluence using dose reconstruction results, 2 cGy more dose
would be delivered to the GTV D95. This adaptation would result in the GTV D95
absorbing 36 cGy less than the planned dose. This correction would result in a slight
improvement to the total target dose.
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A typical patient case is patient 13 (Figure 67-70). The average reconstructed
GTV D95 is 55 cGy greater than the planned D95, while the average actual D95 is 82 cGy
less than the planned. If the plan were to be adapted to achieve the same exit fluence
using dose reconstruction results, 55 cGy less dose would be delivered to the GTV.
This adaptation would result in the GTV absorbing 137 cGy less than the planned dose.
Instead of improving the treatment, this correction would exacerbate the delivery.
The largest discrepancies between backprojected and actual doses happened in
patient 4 (Figure 43-46). The average reconstructed GTV D95 is 123 cGy greater than
the planned D95, while the average actual D95 is 179 cGy less than the planned. If the
plan were to be adapted to achieve the same exit fluence using dose reconstruction
results, 123 cGy less dose would be delivered to the GTV. This adaptation would result
in the GTV absorbing 302 cGy less than the planned dose.

49

Figure 14: Distribution of GTV D95 deviations for each patient. Delivered versus planned deviations are shown by the
blue triangles. Backprojected versus planned deviations are shown by the purple x‘s. The mean deviations between
backprojected and delivered dose are shown by the orange circles.

For each patient, DVH deviation distributions between delivered and planned
dose, as well as between backprojected and planned dose were calculated, along with
the mean deviation between backprojected and delivered dose. The dose indices
examined were GTV D95 (Figure 14), bladder D25 (Figure 82) and D50 (Figure 83), and
rectum D17 (Figure 84) and D35 (Figure 85) (only the GTV plot is shown in this chapter;
all others are shown in Appendix II). For the GTV D95, in some patients (patients 2 and
12), the backprojected dose deviated more from the planned dose than the delivered
dose. In other cases (patients 13 and 14), the opposite held true: the delivered dose
deviated more from the planned dose than the backprojected. The backprojection50

versus-delivered deviations show the effect that adaptation of the plan would have on
the delivered dose. Once again, in some cases the adaptation would bring the
delivered dose closer to the planned dose, but in others it would push it farther away.
The bladder and rectum plots show that while the backprojected dose stays within a few
hundred cGy of the planned dose, the delivered dose varies up to 6000 cGy. The
difference in magnitude is due the fact that dose reconstruction was implemented on the
planning geometry—the structures were in the exact same position for calculation of
both planning and backprojected dose distributions. The delivered dose, however, was
calculated on each patient pose, yielding widely varying bladder and rectum doses due
to their positional variance.
The relationship between exit fluence deviations and patient dose deviations was
examined. For each beam of each patient pose of each patient, the number of pixels
with deviations greater than 5% was determined. Only pixels with dose greater than
20% max dose (i.e. those in the beam) were tabulated. The fraction of pixels with
deviations greater than 5% was then calculated for each patient pose of each patient
geometry. The deviation between delivered and planned GTV D 95‘s were plotted
against the DPI deviations (shown in Figure 15). For each patient pose, the DPI
deviation frequency was averaged over all beams. Lines of best fit were plotted for
each set of data (delivered minus planned, backprojected minus planned, backprojected
minus delivered), and the null hypotheses was tested: that the slope of each line was
equal to zero. The null hypothesis was not rejected (p = 0.08) for the delivered-minusplanned data; the slope of the data could be zero. The null hypothesis was rejected for
the backprojected-minus-planned data (p = 3.4×10-11) and the backprojected-minus-

51

delivered data (p = 0.004). In this instance, DPI deviations were positively correlated to
DVH deviations.

Figure 15: Deviation in GTV D95 versus fraction of DPI pixels that have deviations greater than 5%, for all NKI
patients. The diamonds correspond to differences between the delivered and planned doses. The squares
correspond to differences between the backprojected and planned doses. The triangles correspond to differences
between the backprojected and delivered doses. Respective trend lines are shown. For DPIs, only pixels with dose
greater than 20% of maximum dose were analyzed. For each patient pose, the DPI pixel deviation frequency was
averaged over all beams.

It must be noted that the correlation between DPI deviations and DVH deviations
is not always straightforward. As seen in Figure 15, there are some patient poses which
result in greater than 40% of DPI pixels having deviations greater than 5%, yet there is
less than a 100 cGy GTV D95 difference. Further examination of these patient poses
reveals that DPI deviations were caused by variations in the amount of gas present in
the rectum (see Figure 16). Since beam attenuation through gas is much less than that
through tissue, the difference between the planned and delivered DPIs was greater than
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5% in the area behind the presence of rectal gas. However, the location of the rectal
gas did not cause significant differences between the planned and delivered target
dose. In a few observed patient poses, however, the GTV location was shifted past the
limits of the PTV due to variation in bladder filling (see Figure 17). In this case, even
though the GTV D95 deviation was greater than 500 cGy, there were no DPI deviations
greater than 5%. In these cases, variation in bladder filling did not significantly affect
the patient attenuation.

Figure 16: Coronal slice through the planning pose (left) and a day-of-treatment pose (right). The rectal gas present
in the day-of-treatment pose causes DPI deviations greater than 5% from expected. However, the GTV D 95 deviation
is less than 100 cGy.

Figure 17: Coronal slice through the planning pose (left) and a day-of-treatment pose (right). The filling of the
bladder in the day-of-treatment pose causes the prostate to shift inferior to isocenter, and therefore the GTV D 95
deviation is greater than 500 cGy. However, there are no large patient attenuation differences caused by bladder
filling, and therefore the DPI deviations are less than 5% in all pixels.

To further examine the efficacy of using DPI deviations to predict DVH deviations
a receiver operating characteristic (ROC) curve was generated. The percentage of
failing DPI pixels (i.e. those with deviations greater than 5%) was used as the
independent variable. For each patient pose, the GTV D95 deviations were deemed
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positive or negative based on whether or not they exceeded doses of 50 cGy, 100 cGy,
150 cGy, and 200 cGy. If the DVH deviation exceeded the dose deviation criterion, it
was considered a true or false positive (TP or FP), (true if the DPI deviations were a
correct predictor, false if the DPI deviations were an incorrect predictor). If the DVH
deviation did not exceed the dose deviation criterion, it was considered a true or false
negative (TN or FN). The true positive rate (TPR) and false positive rate, defined as:
TPR = TP / (TP + FN)
FPR = FP / (FP + TN)
were plotted against each other to form ROC curves for each dose deviation criterion.
The ROC curves are shown in Figure 18. A measure of predictive accuracy was
obtained by measuring the area under each curve (AUC)—equaling 0.58 for the 50 cGy
criterion, 0.63 for the 100 cGy criterion, and 0.55 for both the 150 cGy and 200 cGy
criteria. None of the criteria yielded an acceptable predictive quality, as an AUC of 0.63
was not sufficient.
One method to correct for the false positives (e.g. significant DPI deviations, but
insignificant DVH deviations) involves limiting rectal gas via dietary protocol. In fact, the
NKI recommends a dietary protocol of mild laxatives two days prior to imaging or
treatment (Smitsmans, Pos et al. 2008). This protocol resulted in less random
interfraction prostate motion. A method to correct for the false negatives (e.g.
insignificant DPI deviations, but significant DVH deviations) would be to use implanted
markers in the target. Due to their higher electron density, these markers will alter the
attenuation through the patient such that they are visible in the DPI. Thus, the
positioning of the target may be monitored with the EPID. Also, other target-monitoring
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devices could be used to assure that the target has not significantly shifted between
planning and delivery. Detection of implanted markers is discussed in the following
section.

Figure 18: ROC curve showing the predictive value of DPI deviations for GTV D95 deviations with tolerance criteria of
50 cGy, 100 cGy, 150 cGy, and 200 cGy. The dotted black line is the line y = x.

4.2.

Detection of Implanted Markers

The proposal for this work called for both time-of-treatment CTs and DPIs to be
acquired for patients at our institution for the prostate site. Only two patients enlisted in
the prostate protocol at our institution. This protocol included acquisition of a CBCT
while the patient was on the delivery couch, as well as acquisition of DPIs for every
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treatment beam. The protocol also called for Calypso (Seattle, WA) marker implants to
monitor prostate positioning throughout treatment delivery. Therefore it was of interest
as to whether the markers could be detected in measured DPIs for each beam.
Before any patients went through the protocol, an experiment was designed to
determine whether the EPID could detect objects of similar size to Calypso
transponders. While measured exit fluence images can detect the presence of changes
in the patient geometry, they do not necessarily provide a quantitative description of
what those changes are. If objects such as fiducial markers are implanted at precise
locations within the patient geometry, it may be possible to locate them in the exiting
fluence due to their higher attenuation coefficients as compared to the surrounding
normal tissue. The detection of these objects in the measured exit fluence image
provides insight into target location changes during treatment, which is critical for
achievement of dose verification. At our institution, the Calypso system has been
installed to monitor patient position variations during treatment delivery.
Electromagnetic transponders are implanted in the patient and transmit safe
radiofrequency waves which are detected by the Calypso receptor and processed to
determine transponder position. Thus, patient anatomic positional information is gained
during treatment delivery. Although these transponders have a lower atomic density
than gold fiducial markers, they should still be visible in a DPI due to their higher density
as compared to surrounding tissue. If the transponders can be detected in a DPI, then
this provides an opportunity to correlate Calypso‘s positioning measurements with those
determined using the DPI. For patient plans which do not employ the Calypso system,
implanted gold fiducial markers may be used for patient setup, alignment, and
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monitoring. Localization of the markers on the measured DPI will provide knowledge of
the patient geometry during treatment.
For IMRT treatments, identification of markers in DPIs is confounded by patient
scatter, fluence fluctuations caused by the IMRT delivery, and tissue heterogeneities in
the patient. Distinguishing the markers from background becomes difficult due to the
widely varying levels of intensity incident on the patient. To obtain a DPI in which the
objects may be located, a ratio may be taken between the DPI with the patient present
and the DPI without the patient present. With the patient present, the fluence incident
on the EPID could be described as:
patient

where

0

0

( AMLC Apatient

S)

is the fluence exiting the accelerator, AMLC is the attenuation due to the MLC,

Apatient is the attenuation due to the patient, and S is patient scatter. Without the patient
present, the fluence incident on the EPID could be described as:
no patient

0

AMLC

Solving for the attenuation due to the patient, the following equation is obtained:

Apatient

patient
no patient

S

0
no patient

To examine whether an object the size of a transponder could be distinguished
on a DPI of an IMRT field, two standard gold markers were positioned near the prostate
location in a Rando (The Phantom Laboratory, Salem, NY) anthropomorphic pelvic
phantom. DPIs of the IMRT field were acquired both with and without the phantom
present in the beam at a gantry angle of 0º. A simple ratio (which assumes no scatter)
was then calculated between the two images, yielding the attenuation map from the
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phantom. As seen in Figure 19, both gold markers were distinguishable in the ratio
image in areas of both high and low beam intensity. Future work in this study will be to
subtract the estimated scatter from the patient/phantom geometry before the ratio is
calculated. The addition of a scatter filter to the algorithm should cause the markers to
be much more distinguishable. Also, pre-existent code in our institution that
automatically detects markers will be used to automate the detection process (Murphy
and Todor 2005).

Figure 19: Ratio images of DPI with anthropomorphic phantom in the beam and without the phantom in

the beam. The left image corresponds to an accelerating potential of 6 MV, whereas the right image
corresponds to an accelerating potential of 18 MV. The gold markers are circled.

4.2.1. EPID/Calypso Interference
Once the DPIs were obtained for the first fraction of the first patient approved for the
prostate protocol, it was immediately apparent that a significant artifact existed in the
images. The artifact appeared to be caused by an errant readout from the EPID imager
due to the presence of vertical stripes through the images (see Figure 20). It was
hypothesized that the artifact was caused by electronic interference between the EPID
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readout system and the Calypso transponders which were implanted in the patient‘s
prostate. Supporting this hypothesis was the fact that the artifact grew worse when the
EPID was closer to the Calypso receiver used for locating the position of the
transponders. The artifact was most noticeable when the gantry was at 180º, i.e. when
the EPID was at its highest position, and closest to the Calypso detection panel. The
artifact was least noticeable when the gantry was farthest from 180º (for treatment
beams at gantry angles of 30º and 330º).

Figure 20: Example of a through-patient DPI captured during treatment of a prostate site. The gross artifacts,
present both inside and outside the field, were unexpected. It was hypothesized that the artifacts were caused by
interference between the Calypso transponders located in the patient‘s prostate and the readout electronics of the
EPID. The gantry angle for this DPI was 180º.

To test this hypothesis, reproduction of the artifact was attempted in a controlled
setting. A set of Calypso transponders was borrowed from our clinic, and placed upon
the treatment couch, with the Calypso detection panel in its proper place, located above
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the couch. The gantry was rotated to 180º, and the EPID was extended above the
Calypso panel at SDDs ranging from 125 cm to 150 cm. Control images of two fields (a
flood field and a 10×10 cm2 field) were acquired while the Calypso monitoring remained
inactive. Test images were then acquired with the Calypso monitoring active. A ratio of
the active to inactive Calypso images for the 10×10 cm2 field is shown in Figure 21.
Differences as large as an order of magnitude were seen outside of the field. An
indirect relationship was confirmed between the artifact severity and distance between
the EPID and Calypso panel.
It was hypothesized that this artifact could be removed by constructing a Faraday
cage around the EPID to remove any electronic interference from the Calypso panel.
The same measurements described in the previous paragraph were re-acquired, except
with a rudimentary Faraday cage protecting the EPID. The cage was constructed out of
overlapping pieces of aluminum foil wrapping around the outer shell of the EPID. As
shown in Figure 22, the severity of the artifact was reduced by an order of magnitude.
Profiles across the left-right and inferior-superior directions are shown in Figure 23 and
Figure 24. Even with the reduction of the artifact, they were still too large to detect the
implanted transponders. Therefore, no more measurements were analyzed for the
dose verification study.
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Figure 21: Ratio of the 10×10 cm field acquired with active Calypso tracking to that without Calyspo tracking. The
field is marked by the dashed black line. Artifacts as large as an order of magnitude are seen outside the field.
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Figure 22: Ratio of the 10×10 cm field acquired with active Calypso tracking and a rudimentary Faraday cage
surrounding the EPID to that without Calypso tracking or Faraday cage. Artifacts were reduced by an order of
magnitude outside of the field. Deviations along the field edges were due to slight variation in the jaw positions
between acquisition of the two DPIs.
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Figure 23: Profile along the left-right direction for a 10×10 cm field for a non-Calypso/non-Faraday cage set-up
(green line), a Calypso/non-Faraday cage set-up (blue line), and a Calypso/Faraday cage set-up (red line). The
green line represents normal acquisition of a DPI. The blue line represents the artifact caused by electronic
interference between the EPID readout and Calypso transponder tracking. The red line represents the correction for
the artifact by enclosing the EPID in a rudimentary Faraday cage. The ―ripples‖ in the middle of the profile are
caused by attenuation of the case containing the transponders on the couch.
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Figure 24: Profile along the superior-inferior direction for a 10×10 cm field for a non-Calypso/non-Faraday cage setup (green line), a Calypso/non-Faraday cage set-up (blue line), and a Calypso/Faraday cage set-up (red line). The
green line represents normal acquisition of a DPI. The blue line represents the artifact caused by electronic
interference between the EPID readout and Calypso transponder tracking. The red line represents the correction for
the artifact by enclosing the EPID in a rudimentary Faraday cage.

4.3.

DRR Simulations

Closing the loop of IGART via DPI comparison requires accurate simulation of the
expected DPI. Sensitivity of comparisons should increase as the amount of time
decreases between the image used for DPI simulation and the treatment time DPI
measurement as there is less time for the patient to change. Depending on the clinic
and patient protocol, the most recent patient geometry could range from the planning
FBCT (taken several days in advance) to a CBCT acquired moments before the
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treatment delivery begins. Therefore a balance must be struck between the accuracy
and the speed of DPI simulation.
In non-time critical situations, MC simulation of radiation transport to
simultaneously determine patient dose and the exit fluence DPI provides an accurate
method to perform delivery verification. However, dose calculation for online IGART
treatment evaluations is not feasible with pure MC techniques due to computation time.
Nonetheless, in these cases post-treatment delivery validation can be performed when
daily treatment adaptations occur. This process, however, only permits offline closed
loop adjustments. Greater speed DPI calculations are required for online IGART.
A through-patient DPI consists of two fluence components incident upon the
EPID: 1) the attenuation of the incident fluence through the patient, termed DPIatt, and
2) the scattered radiation produced within the patient, termed DPIscat. The DPI
calculation is therefore separable, and each component has the potential to be
computed using faster techniques. An estimate of DPIatt may be obtained by calculating
the attenuation along the ray through the patient geometry to each detector pixel.
These calculations are called digitally reconstructed radiographs (DRRs). An estimate
of DPIscat component may be obtained from MC models, if there is low variation of the
component caused by variation in patient anatomy. This section describes
development of DRR-based DPI calculations, with MC calculation through the same
geometries used as a reference standard.

4.3.1. DRR Calculation
A DRR patient attenuation model was created by modifying an in-house DRR algorithm.
Inputs for the original in-house DRR code include 1) the source definition, which is
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taken to be a mono-energetic point source, 2) the patient CT geometry through which
the incident source fluence is projected, and 3) the detector geometry, which is a simple
plane of pixels. The original DRR generator ray traced through the patient geometry
from a point source located at the accelerator target location. In performing the ray
trace, the provided code simply added pathlengths through the geometry as opposed to
computing exponential attenuation. Siddon‘s technique was used for ray tracing
(Siddon 1985).
This in-house DRR code was adapted for calculating the primary transmission of
a megavoltage beam through a patient geometry. Three major changes were
implemented. First, the code was updated to handle poly-energetic beams as input by
using a fluence-weighted sum of mono-energetic calculations. For both 6 MV and 18
MV accelerating potentials, the beam energy spectra were modeled according to Mohan
(Mohan, Chui et al. 1985), with energy bins of 0.5 MeV. Secondly, the patient CT was
transformed from CT-number information to meaningful attenuation information, i.e.

,

where

is the mass attenuation coefficient and

Since

is dependent on beam energy, per-energy-bin instances of the patient geometry

were created. The per-energy values of

is the density of the voxel material.

were derived using XCOM (Berger, Hubbell

et al. 1998), a photon cross sections database provided by the National Institute of
Standards and Technology (NIST). Finally, the model for attenuation was updated from
an additional to an exponential one.
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Figure 25: Irregular phantom created for geometric validation of the DRR model. The incident beam, directed into
the page, is shown in yellow.

Figure 26: DRR-generator GUI. The GUI is used to set options describing the geometry of the beam, phantom, and
imager, based on a user-selected input file (seen in top left). The ―Calculate DRR‖ button is then pressed, which calls
the DRR simulation code to run. The generated DRR is then displayed in the panel on the right.
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Primary attenuation for the DRR-based DPI-generator was benchmarked via
comparison with an MC-generated exit fluence (discussed in Section 3.2.1). I coded in
the ability to separate the MC-generated exit fluence into primary and scatter
components, permitting this comparison. For the MC calculations, instead of using the
full head source model, a simple point source was coded by changing the directional
components of each sourced particle and forcing them to have the same origin at the
target location (0,0,0), thereby allowing for comparison to the simple DRR point source.
To verify that the geometry of the DRR was consistent between the DRR and MC codes
(i.e. the patient geometry and scoring plane were in the correct position relative to the
point source), an irregular water phantom was created and is shown in Figure 25.
Delivery information stored in the TPS was transferred manually to both the DRR and
MC codes for input. This information included beam energy, patient/phantom geometry,
and imager geometry. One billion photons were simulated incident on the testing
phantom for the MC calculation, which required slightly less than three hours of
computer time (on a single CPU). DRR-generation required approximately one minute
(on a single CPU), of which the majority was spent loading the phantom geometry into
the code system. The DRR calculation itself took less than ten seconds. The graphical
user interface (GUI) for the DRR generator is shown in Figure 26.
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Figure 27: Comparison of DPIs simulated through an irregular water phantom by the primary component of an MC
calculation (top left) and by a point-source DRR calculation (bottom left). The difference map, measured in percent
with respect to maximum intensity, is shown in the top right panel. Profile intensities along the dashed black line of
the images are shown in the bottom right panel. The blue data refers to the MC-generated DPI, while the green data
refers to the DRR-generated DPI.

The DRR- and MC-generated images are compared in Figure 27. Differences up
to ten percent of maximum intensity were observed along the edges of the irregular
phantom. While the MC-generated image showed a softer gradient in these areas, the
DRR-generated image displayed very sharp edges. In low-gradient areas, however, the
DPIs agreed within two percent. It was shown that the TPS information was
successfully transferred to the DRR system, and that the DRR-generator correctly
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modeled the geometry of the beam, patient, and imager. Planned future development
of the DRR code includes IMRT capabilities and a more fully automated system.

4.3.2. Patient Scatter Model
It was hypothesized that patient exit scatter variation was insignificant with respect to
the total exit fluence, and therefore a single scatter estimate would be valid for all
patient poses. An estimate of the patient scatter contribution to the exit fluence was
obtained by using MC simulations to compute the scatter contribution to the exit fluence
for each image of each patient from the NKI prostate patient database (described in
Section 3.2.2). Since the VMC++ MC code used in this study does not have a ―latch bit‖
(which, in other MC codes, defines the geometry of last interaction for each particle), a
module was written which enabled separation of primary and scatter components. First,
the MC source model was modified to bank particles to an exit particle handler. This
consisted of saving the phase space coordinates of the source model particle. Phase
space coordinates (u,v,w) of particles exiting the MC patient geometry were compared
to those of the source model particle. If the energy and direction differed by less than
round-off error, the particle was labeled a primary particle; if not, the particle was
labeled as scatter. The exit scatter fluence was then convolved with the EPID fluenceto-dose energy deposition kernels at the imager surface to produce the scatter DPI.
The per-pixel standard deviation of these DPIs was then calculated over the set of all
geometries for each patient. This scatter variation was then divided by the maximum of
the mean total DPI (primary plus scatter), to determine the significance of the variation
in the scatter component as compared to the total DPI.
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For a single patient case, plots of the scatter variation, both by itself and
compared to maximum mean total dose, are shown in Figure 28. For this patient, DPIs
were simulated through eleven geometries. The per-pixel relative standard deviation of
the scatter component for each beam ranged up to 8% of the scatter DPI imager dose.
When compared to the maximum total imager dose for each beam, however, the impact
of the scatter variation is minimal: for this patient, it is less than 0.2%. The mean and
maximum per-pixel scatter variations (with respect to total imager dose) for each patient
are shown in Table 5. The mean per-pixel scatter variation with respect to total dose
was averaged over all beams for each patient, while the maximum per-pixel variation
was determined over all beams as well. The largest mean scatter variation was on the
order of 0.1%, and the largest maximum scatter variation was on the order of 0.6%.
Table 5: Mean and maximum per-pixel standard deviations for the scatter component of the exit image. These
values were calculated with respect to maximum total dose. The mean scatter variation for each patient was
averaged over all beams, while the maximum scatter variation was found over all beams.

1

Mean scatter
variation (%)
0.12

Max scatter
variation (%)
0.41

11

Mean scatter
variation (%)
0.07

Max scatter
variation (%)
0.20

2

0.11

0.40

12

0.07

0.21

3

0.13

0.60

13

0.05

0.15

4

0.05

0.15

14

0.06

0.19

5

0.11

0.51

15

6

0.10

0.33

16

0.11

0.37

7

0.07

0.21

17

8

0.09

0.25

18

0.14

0.46

9

0.11

0.41

19

0.08

0.23

10

0.14

0.47

Patient

Patient
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Scatter variation w.r.t. total fluence (%)

Scatter variation (%)

Figure 28a: Scatter variation for patient 1, scaled in percentages. The left column shows the per-pixel relative
standard deviation of the scatter DPI through a series of eleven patient geometries. The right column shows the
same scatter variation, but in relation to the maximum mean total DPI. Only the DPI area within 2 cm of the beam is
included. Gantry angles of 180º, 230 º, 280 º, and 330 º are shown on the following pages.
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Scatter variation w.r.t. total fluence (%)

Scatter variation (%)

Figure 13b: Scatter variation for patient 1, scaled in percentages. The left column shows the per-pixel relative
standard deviation of the scatter DPI through a series of eleven patient geometries. The right column shows the
same scatter variation, but in relation to the maximum mean total DPI. Only the DPI area within 2 cm of the beam is
included. Gantry angles of 30º, 80 º, 130 º, and 330 º are shown on the previous and following pages.
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w.r.t. total fluence (%)

Scatter variation (%)

Figure 13c: Scatter variation for patient 1, scaled in percentages. The left column shows the per-pixel relative
standard deviation of the scatter DPI through a series of eleven patient geometries. The right column shows the
same scatter variation, but in relation to the maximum mean total DPI. Only the DPI area within 2 cm of the beam is
included. Gantry angles of 30º, 80 º, 130 º, 180 º, 230 º, and 280 º are shown on the previous pages.

For all patients, the scatter variation of the DPI was observed to have
insignificant impact (less than 0.2%) when compared to the total intensity of the DPI, as
shown in Table 5. Therefore, when simulating a DPI by combining a DRR calculation
with a scatter component, it is unnecessary to estimate the scatter through each
individual patient geometry. Since scatter variation is a insignificant with respect to
fluence variations caused by changes in the patient geometry, the scatter component of
the exit fluence for a patient pose can be estimated by the MC-derived scatter
component of the planning geometry exit fluence. Addition of the planning exit scatter
fluence to the day-of-treatment DRR-generated primary exit fluence yields an estimate
of the expected during-treatment exit fluence, which will be compared to the per-beam
DPIs measured during each fraction of treatment delivery.

4.4.

Significance of Findings

Since there was positive correlation between the DVH deviations and DPI deviations,
there is potential to reduce patient dose reconstruction errors caused by the
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backprojection assumption. For this dataset, the amount of time that elapsed between
acquisition of the planning CT and day-of-treatment CT images varied from a few days
to several weeks. Exit fluence deviations caused by changes in patient geometry
should decrease as the time between imaging and treatment decreases. In an ideal
situation, the patient would be imaged as the treatment is delivered, thereby giving
complete knowledge of the geometry through which dose is delivered and the DPI is
acquired. In this case, the delivered dose could be reconstructed with no errors
introduced by the backprojection assumption.
Although it is currently unfeasible to image the patient during treatment, it is
possible to image them immediately prior to treatment delivery. Some delivery systems
have a CBCT system for pretreatment imaging. Acquiring a CBCT of the patient
immediately prior to treatment delivery—and using that geometry for backprojection—
would reduce the exit fluence deviations caused by assuming the backprojection
geometry is the same as the planning geometry. However, exit fluence deviations,
although reduced, will persist due to changes in the patient geometry between
acquisition of the CBCT and delivery of the treatment immediately thereafter.
One disadvantage of imaging the patient before each fraction of delivery is the
extra dose that this CT imaging causes. A daily CBCT would not be necessary for a
patient geometry which does not vary significantly from fraction to fraction. In these
cases, generating DPIs through previous patient geometry incidences should suffice for
treatment verification. A potential application of this work in exit fluence dosimetry is to
set tolerance levels for exit fluence deviations such that if deviations exceed the level,
then the patient should be re-imaged immediately after treatment delivery.
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Differences between expected and measured DPIs will always exist because 1)
the patient geometry always deforms both inter- and intrafractionally, and 2) the beam
characteristics have an inherent variation. Thresholds theoretically can be determined
which will distinguish between clinically significant and insignificant deviations. Based
on these tolerances, it will be possible to predict when exit fluence deviations indicate
significant deviations between the planned and delivered patient doses. Thus, dose
verification will be performed. However, as has been shown by my backprojectionbased dose reconstruction, misattributing a source of exit fluence deviation may result
in a poorer estimate of the patient dose. Therefore, it is critical to determine the source
of DPI deviations to judge not only how delivery verification should be performed, but
also whether the delivery was within tolerance.
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Figure 29: Decision tree showing how to process DPI deviations. If the differences are insignificant, dose
reconstruction is performed to achieve delivery verification. If the differences are significant, the source of the
differences is determined by comparing the deviation map with a bank of known deviations. This comparison will
show whether the differences were caused by changes in the patient geometry, changes in the machine-delivered
fluence, or a combination of the two.

To address this, a decision tree for how to deal with DPI deviations was
developed and is shown in Figure 29. The process begins with simple comparison of
the measured and expected DPIs. If significant differences do not exist, then patient
dose reconstruction may be performed if the physicist desires to analyze DVHs. If
significant differences do exist between the measured and expected DPIs, further action
is required. The process continues with classification of the deviation according to its
source by comparison with respect to a library of previously-known deviation maps and
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probably sources of error. When the comparison shows that the deviations were
caused by changes in the machine-delivered fluence, then the expected DPI should be
re-simulated using the entrance fluence formed by the MLC leaf positions which were
recorded during treatment (in files called ―dynalogs‖). When the deviation is attributed
to patient anatomical changes, a better estimate of the patient geometry is necessary,
either by re-imaging the patient or adjusting the prior image before dose evaluation. If
the deviation map is dissimilar to any in the library of known deviations, the patient
geometry should be examined to find the sources of the differences. Once the source is
determined, it will be added to the library of known deviation maps for future matching
purposes. The patient dose may then be reconstructed with a known uncertainty. If the
uncertainty is significant, then dose reconstruction-based delivery verification will not be
performed.
Correlation between DPI and DVH deviations must be further examined to obtain
a more accurate predictor of treatment delivery failure. In this work, the only predictor
examined was frequency of DPI pixel deviations greater than 5%, which resulted in an
ROC curve showing accuracy of only 0.63. To increase this accuracy, combinations of
other DPI deviation characteristics should be examined, such as greater or lower DPI
deviation thresholds, or areas of DPI deviations. An increase in predictor accuracy is
necessary for DPI-based dose verification to be effective.
This study was limited to the prostate site, where typical patient anatomy
variations include bladder and rectal filling. Correlation between DPI and DVH
deviations should also be examined at different sites such as H/N and lungs, where
heterogeneity is more prevalent, leading to a higher variation in patient attenuation.
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DPI-based verification should detect shrinkage of H/N tumors over the treatment
course, as well as changes in the target size and shape in lung tumors over the
treatment course.
The final step of closing the loop of IGART is development of a system which
calculates the DPI deviations, evaluates whether the deviations are within tolerance,
and recommends how to proceed. This system should be located in the treatment
control room, where the user will be able to monitor the reported deviations and have
the option of stopping treatment if necessary. The development of this tool is discussed
in the following chapter.
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5. Dose Verification Graphical User Interface

Although there are several commercial EPID-based dose verification products, no
existing product met the specific needs of this research study. For example, Varian
(Palo Alto, CA) offers a ‗PortalVision‘ tool whose image prediction algorithm is based on
Van Esch‘s work (Van Esch, Depuydt et al. 2004). PortalVision allows for comparison
of measured and simulated portal images; however, it is limited to pretreatment
verification (i.e. no patient in the beam) and bases its image analysis on Low‘s gamma
metric (Low and Dempsey 2003). Another product is available from Standard Imaging
(Middleton, WI); however, it utilizes pretreatment fluence measurements to reconstruct
dose on the patient‘s planning image. Deconvolution of the portal image yields the
incident fluence, which is then used to simulate the delivered patient dose on the
planning patient geometry. Verification is achieved when this ‗delivered‘ patient dose is
compared to and agrees with the planned patient dose within tolerance. In addition to
commercial products available, several institutions have produced in-house verification
tools for their own clinics (van Zijtveld, Dirkx et al. 2006; Mans, Wendling et al. 2010).
The goal of this work is to provide our clinic with an in-house EPID-based verification
tool, to be used for both pretreatment and, eventually, during-treatment delivery
verification.

80

5.1.

Current Clinical Practice

IMRT treatments were implemented at VCU in 1998. The original method used for
pretreatment IMRT QA was purely radiographic film-based. Starting in 2000, an
independent MC calculation was also performed. Film was replaced with the EPID in
2003, while MC simulation continued. This previous EPID-based system was
qualitative in nature—the physicist would simply use a naked-eye determination of
whether the field was adequately delivered. Starting in 2009, the EPID-based system
was replaced with one using an I‘mRT Matrixx (IBA Dosimetry America, Bartlett, TN)
two-dimensional array of ionization chambers. This device has 1020 ionization
chambers spaced out over an area of 24.4 × 24.4 cm2, providing a resolution of 0.8 cm.
During pretreatment verification, the Matrixx is placed on the treatment couch to capture
the measured beams. The measured images are then automatically imported to a
verification GUI, which compares measured and expected images using the gamma
metric (3%, 3 mm). Since the DTA tolerance is less than the resolution of the Matrixx,
the measured images are interpolated for gamma calculations. For each field the GUI
shows both the measured and expected image, a profile through the images, and the
resulting gamma comparison image. A printout is obtained from the GUI containing
these images along with the gamma statistics, treatment and patient information, and
appropriate signature lines (see Figure 30).
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Figure 30: Sample printout from the I‘mRT Matrixx verification system. The expected and measured fields are
displayed on the left side, while the right side shows both a user-selected profile across both images, as well as the
gamma comparison image. Treatment plan information is displayed at the bottom along with gamma results and
appropriate signature lines.
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Utilizing the Varian aS1000 EPID instead of the Matrixx allows for improvements
in delivery verification in several areas. Physically, the EPID has a detection area that
is twice as large (40 × 30 cm2) as the Matrixx, and a resolution that is up to twenty times
higher (0.04 cm). The EPID is also attached to the gantry, and may be automatically
positioned and retracted from the control room, avoiding the time required to manually
position the Matrixx for each verification session and allowing QA to be performed using
treatment settings (e.g. gantry angle, collimator angle, etc…). The motivation for
changing to an EPID-based verification system is to allow QA of larger treatment fields,
detection of smaller treatment delivery errors (due to the higher resolution), and ideally
implementation of a speedier process.

5.2.

GUI-based Tool

Both a clinical and an expert/research version of the delivery verification tool were
created using MATLAB (MathWorks, Natick, MA). For the clinical version, emphasis
was placed on simplicity of the user interface and speed, qualities which would be both
necessary and beneficial to improve efficiency in the clinical verification process. For
the research version, more options are available to the user for preprocessing of the
images as well as more comparison metrics to allow for judgment of verification.

5.2.1. Clinical Version
The interface for the clinical version of the tool is shown in Figure 31. When operating
the clinical version of the verification GUI, the user first selects the directories for both
the calculated expected images and the measured images. Once the directories have
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been selected, all images are automatically detected in each directory. The GUI is able
to import several image formats:
DICOM (Digital Imaging and Communications in Medicine) – The record and
verify system used at our clinic exports measured images in this format.
dxf (Drawing Interchange Format) – Another format for exported measured
images through our record and verify system.
hna – The format used when acquiring images in the service mode with IAS
Monitor.
binary MC – our in-house MC system simulates EPID images which use this
binary storage format.
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Figure 31: EPID-based delivery verification GUI designed for clinical use. The expected image is displayed in
the upper left panel, while the measured image is displayed in the upper right panel. The resulting gamma
comparison image is displayed in the lower right panel. Buttons in the lower left panel allow for scrolling among
all of the fields for a given patient, as well as printing out the QA report for the patient. The table shows the
gamma results for each field, as well as whether the field passed or failed the given criteria (in this case, a 3 mm
distance-to-agreement and a 3% dose difference).

Ideally, for every measured image in the measured directory, there is a
corresponding calculated image in the calculated directory. If this is not the case, the
GUI reports that image(s) are missing from the appropriate location(s). The GUI then
populates a list of all images that are located in both directories and imports them. The
user may then scroll through and visualize each pair of images. The GUI uses header
information from each image to automatically adjust for imager location and resolution.
The next step of the verification process is for the user to click the ―Compare All
Images‖ button, which performs a gamma comparison between the two images. The
default criteria for passing gamma at our clinic is
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Where P is the percentage of pixels with gamma values less than 1 (i.e. passing
gamma) for criteria of 3 mm distance-to-agreement and 3% dose difference. Gamma
values are only calculated for pixels with intensity greater than 20% of maximum pixel
intensity. The gamma calculation requires approximately five seconds per field. After
the calculations are finished, the gamma image is displayed next to the corresponding
measured and calculated images. The user may scroll through each field to visualize
where any significant differences occur. The gamma results are also displayed in table
form on the GUI. As the user scrolls through each field, the verification result is
highlighted on the GUI as well. If 95% of the pixels pass gamma (3%, 3 mm), a large
―PASS‖ is displayed with a green background. If the images fail the gamma criteria, a
large ―FAIL‖ is displayed with a red background. If the percentage of pixels passing
gamma is between 90% and 95%, a large ―WARNING‖ is displayed with a yellow
background, and the user is advised to manually inspect the differences.

86

Figure 32: Sample QA printout that is auto-generated by the clinical DPI comparison GUI. The calculated and
measured fields are shown, as well as the corresponding 3 mm / 3% gamma image and a profile comparison image.
Field information is shown at bottom as well as a signature line for the verification.
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The final step of the clinical process is to print the QA report for the treatment
plan. As seen in Figure 32, the printout was designed to reflect the same information
that was produced in the Matrixx QA printout: images of the fields, profiles through the
fields, the gamma image, and plan information and signature lines. For each field in the
plan, a soft-copy QA report is saved to disk (in html format) and a hard-copy is sent to
the local printer. When the user is finished with verification for a specific patient, the
verification results are automatically copied to a research database, allowing for further
future analysis.

5.2.2. Research Version
Beyond the clinical mode, this tool provides an excellent framework for analysis of
images. Therefore, a research version of the interface was also designed which
allowed for more manipulation of images as well as various comparison metrics besides
the gamma metric. The research interface is shown in Figure 33. Similar to the clinical
interface, the first step is for the user to select the directories for the reference and test
images. The user is then required to select the individual images for comparison from
each directory, as the research version was designed for comparison of single images,
not groups of images.
Prior to comparison, each image may be preprocessed in a number of ways. If
image noise is a concern, a boxcar filter of user-chosen size may be applied. Output
normalization may be performed between the two images. The normalization is
calculated by multiplying the test image by the ratio of the sum of all pixels greater than
10% maximum intensity in the reference image divided by the same pixels in the test
image.
88

A sub-pixel fast-Fourier-based rigid registration (Guizar-Sicairos, Thurman et al.
2008) was also coded into the GUI as an option. To test the accuracy of the
registration, a reference field was randomly rotated and translated to form one hundred
test images, which were then registered back to the reference image. For every test
image, the registration was found to be accurate within half of a pixel and half of a
degree. Since the registration algorithm did not account for scaling (i.e. differences in
the zoom between the two images), an optional zoom factor correction was coded into
the GUI as well. The zoom factor also incorporated the inverse-square law for adjusting
the intensity of the image. The intensity adjustment assumes that differences in the
zoom factor between two images are due to differences in the location of the imager in
the z-plane.
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Figure 33: EPID-based delivery verification GUI for research purposes. The two imported images are displayed in
the top panels, and the comparison image is displayed in the bottom right panel. Comparison metrics available are a
percent difference image, a gamma image, and a pixel intensity deviation (PID) histogram. The result of the
comparison is shown in the lower left corner (in this case, the test image passed the accepted tolerance).

The research version of the verification tool also provides several other
comparison metrics in addition to the gamma metric, which allows for more
comprehensive analysis of image deviations:
A simple percent difference image can be calculated and displayed. The
pixel-by-pixel histogram of the percent difference image, termed the pixel
intensity distribution (PID), can also be displayed. The PID comparison
metric was published in Medical Physics (Gordon, Gardner et al. 2012).
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If the user desires to analyze a series of images, and not just one single
image against another, there is capability to calculate a series sigma image.
In this calculation, the GUI finds all images located in the selected directory,
and, for each pixel of the images, calculates the standard deviation of the
pixel intensity over all of the images. This analysis is useful to reveal
problematic areas of delivery in a field, whether caused by machine-related
sources of deviation (e.g. jaw location uncertainty) or patient-related sources
of uncertainty (e.g. presence of air pockets in the rectum).
If two MC images are being compared, and the corresponding uncertainty
images exist, then a ―Kawrakow-Fippel‖ (KF) comparison may be performed
(Kawrakow and Fippel 2000). This analysis reveals areas that differ
significantly between the two images with respect to their corresponding pixel
uncertainties. The user may display the KF image or the histogram of KF
pixel values.
All analysis results can be saved to disk as image files or pdf files.

5.3.

Future Improvements

Implementation of the verification tool into our clinic will start with several test QA cases,
where past patient treatment information will be used both to calculate and measure
portal images for several patients. The appropriate staff will then be trained in how to
use the GUI to import these images and then perform verification.
The next step in automation of the verification process is to implement automatic
generation of calculated images into the treatment planning process, as well as
automatic placement of the calculated and measured images. The tool will be further
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developed so that it will regularly automatically search for new calculated and measured
images in the appropriate directories. When matching images are detected, it will
perform the comparison automatically in the background. This process allows for a
more efficient final manual review for each patient QA. The user can view several
patient comparison results consecutively, instead of waiting for the comparison
calculations to be performed between viewing of each set of patient fields.
During-treatment QA in the verification process is also desired. The goal of
during-treatment verification is to avoid gross errors in treatment delivery. Instead of
waiting to perform verification until after the treatment fraction is complete, duringtreatment cine images will automatically be imported into the GUI, and compared to the
predicted images, all while the patient is being treated. These comparisons will
inherently incorporate errors due to assumptions made about the unknown patient
geometry, however, gross deviations (e.g. wrong field, jaw settings, MU, etc…) between
the measured and calculated images will still be detectable, and the delivery may be
stopped mid-treatment.
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6. Conclusion

The EPID is a useful tool for treatment QA due to its dosimetric stability and convenient
positioning on the linac gantry arm. The aim of this work was to improve upon EPIDbased dose verification for ART.
Software was developed which improved our institution‘s ability to simulate
expected DPIs. The ability to separate the primary and scatter portions of DPIs was
implemented. Also, exit fluences can now be outputted as well as DPIs. A basic
backprojection component was added to our MC system, allowing for backprojectionbased dose reconstruction in instances where it is deemed appropriate.
The basic assumption of backprojection-based dose reconstruction, that variation
in exit fluence is caused by machine-related variability, was tested and found to be
erroneous. Interfractional changes in the patient anatomy caused significantly larger
deviations in exit fluence than the inherent variation in the machine-delivered fluence.
Exit fluence deviations must not simply be attributed to entrance fluence deviations,
allowing for a potentially faulty patient dose reconstruction for delivery verification.
Without knowledge of the during-treatment patient anatomy, dose reconstruction could
potentially result in a worse estimate of the delivered dose than the planned dose itself.
Therefore caution is recommended whenever dose reconstruction is desired.
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Correlation between DPI deviations and DVH deviations was observed, and false
positives and negatives were examined. Although positive correlation was found,
further work must be performed to achieve a higher accuracy in using DPI deviations as
a predictor for DVH deviations. A decision tree was proposed detailing when DPI-based
delivery verification must be sufficient, and when dose reconstruction-based delivery
verification is permissible. Potential DPI deviation tolerances were examined which
predict when there are significant differences between the planned and delivered dose.
Also, failure to meet tolerance could dictate that the patient anatomy should be reimaged.
A semi-automated dose verification tool was developed for implementation at this
institution, both for clinical and research purposes. The clinical tool allows for
comparison of pretreatment or during treatment DPIs, and provides a measurement of
treatment delivery success. The research tool includes several other means of
comparison of two or more DPIs, and allows the user to manipulate the images
throughout the comparison. Currently, the tool will determine if any egregious delivery
errors have occurred, and report to the user whether the delivery passed within
tolerance. The framework for implementation of an EPID-based dose verification
system at this institution was completed, which will result in both a more efficient and
more accurate verification process than the current system.
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Figure 34: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 1. The planned doses are shown
as the bolded black solid lines. For each simulated treatment fraction, both the delivered doses (thin solid lines) and
reconstructed doses (dashed lines) are shown. Beam energy for this patient was 6 MV.
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Figure 35: GTV DVHs for patient poses [01, 02 …] for patient 1. The planned dose is shown as the bolded black
solid line. For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses
(dashed lines) are shown. Beam energy for this patient was 6 MV.

109

Figure 36: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient 1.
The x-axes represent the dose difference in units of cGy. The numbers in the red/green boxes represent the mean
differences. For the D95 values, the average delivered dose is 75 cGy greater than the average reconstructed dose.
Beam energy for this patient was 6 MV.
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Figure 37: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 2. The planned doses are shown
as the bolded black solid lines. For each simulated treatment fraction, both the delivered doses (thin solid lines) and
reconstructed doses (dashed lines) are shown. Beam energy for this patient was 6 MV.
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Figure 38: GTV DVHs for patient poses [01, 02 …] for patient 2. The planned dose is shown as the bolded black
solid line. For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses
(dashed lines) are shown. Beam energy for this patient was 6 MV.
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Figure 39: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient 2.
The x-axes represent the dose difference in units of cGy. The numbers in the red/green boxes represent the mean
differences. For the D95 values, the average delivered dose is 177 cGy greater than the average reconstructed dose.
Beam energy for this patient was 6 MV.
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Figure 40: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 3. The planned doses are shown
as the bolded black solid lines. For each simulated treatment fraction, both the delivered doses (thin solid lines) and
reconstructed doses (dashed lines) are shown. Beam energy for this patient was 6 MV.
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Figure 41: GTV DVHs for patient poses [01, 02 …] for patient 3. The planned dose is shown as the bolded black
solid line. For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses
(dashed lines) are shown. Beam energy for this patient was 6 MV.
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Figure 42: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient 3.
The x-axes represent the dose difference in units of cGy. The numbers in the red/green boxes represent the mean
differences. For the D95 values, the average delivered dose is 18 cGy greater than the average reconstructed dose.
Beam energy for this patient was 6 MV.
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Figure 43: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 4. The planned doses are shown
as the bolded black solid lines. For each simulated treatment fraction, both the delivered doses (thin solid lines) and
reconstructed doses (dashed lines) are shown. Beam energy for this patient was 18 MV.
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Figure 44: GTV DVHs for patient poses [01, 02 …] for patient 4. The planned dose is shown as the bolded black
solid line. For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses
(dashed lines) are shown. Beam energy for this patient was 18 MV.
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Figure 45: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient 4.
The x-axes represent the dose difference in units of cGy. The numbers in the red/green boxes represent the mean
differences. For the D95 values, the average delivered dose is 302 cGy greater than the average reconstructed dose.
Beam energy for this patient was 18 MV.
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Figure 46: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 5. The planned doses are shown
as the bolded black solid lines. For each simulated treatment fraction, both the delivered doses (thin solid lines) and
reconstructed doses (dashed lines) are shown. Beam energy for this patient was 6 MV.
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Figure 47: GTV DVHs for patient poses [01, 02 …] for patient 5. The planned dose is shown as the bolded black
solid line. For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses
(dashed lines) are shown. Beam energy for this patient was 6 MV.
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Figure 48: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient 5.
The x-axes represent the dose difference in units of cGy. The numbers in the red/green boxes represent the mean
differences. For the D95 values, the average delivered dose is 239 cGy greater than the average reconstructed dose.
Beam energy for this patient was 6 MV.
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Figure 49: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 6. The planned doses are shown
as the bolded black solid lines. For each simulated treatment fraction, both the delivered doses (thin solid lines) and
reconstructed doses (dashed lines) are shown. Beam energy for this patient was 6 MV.
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Figure 50: GTV DVHs for patient poses [01, 02 …] for patient 6. The planned dose is shown as the bolded black
solid line. For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses
(dashed lines) are shown. Beam energy for this patient was 6 MV.
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Figure 51: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient 6.
The x-axes represent the dose difference in units of cGy. The numbers in the red/green boxes represent the mean
differences. For the D95 values, the average delivered dose is 128 cGy greater than the average reconstructed dose.
Beam energy for this patient was 6 MV.
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Figure 52: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 7. The planned doses are shown
as the bolded black solid lines. For each simulated treatment fraction, both the delivered doses (thin solid lines) and
reconstructed doses (dashed lines) are shown. Beam energy for this patient was 18 MV.
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Figure 53: GTV DVHs for patient poses [01, 02 …] for patient 7. The planned dose is shown as the bolded black
solid line. For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses
(dashed lines) are shown. Beam energy for this patient was 18 MV.
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Figure 54: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient 7.
The x-axes represent the dose difference in units of cGy. The numbers in the red/green boxes represent the mean
differences. For the D95 values, the average delivered dose is 36 cGy greater than the average reconstructed dose.
Beam energy for this patient was 18 MV.
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Figure 55: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 8. The planned doses are shown
as the bolded black solid lines. For each simulated treatment fraction, both the delivered doses (thin solid lines) and
reconstructed doses (dashed lines) are shown. Beam energy for this patient was 6 MV.
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Figure 56: GTV DVHs for patient poses [01, 02 …] for patient 8. The planned dose is shown as the bolded black
solid line. For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses
(dashed lines) are shown. Beam energy for this patient was 6 MV.
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Figure 57: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient 8.
The x-axes represent the dose difference in units of cGy. The numbers in the red/green boxes represent the mean
differences. For the D95 values, the average delivered dose is 71 cGy greater than the average reconstructed dose.
Beam energy for this patient was 6 MV.
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Figure 58: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 9. The planned doses are shown
as the bolded black solid lines. For each simulated treatment fraction, both the delivered doses (thin solid lines) and
reconstructed doses (dashed lines) are shown. Beam energy for this patient was 6 MV.
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Figure 59: GTV DVHs for patient poses [01, 02 …] for patient 9. The planned dose is shown as the bolded black
solid line. For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses
(dashed lines) are shown. Beam energy for this patient was 6 MV.
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Figure 60: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient 9.
The x-axes represent the dose difference in units of cGy. The numbers in the red/green boxes represent the mean
differences. For the D95 values, the average delivered dose is 23 cGy greater than the average reconstructed dose.
Beam energy for this patient was 6 MV.
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Figure 61: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 11. The planned doses are
shown as the bolded black solid lines. For each simulated treatment fraction, both the delivered doses (thin solid
lines) and reconstructed doses (dashed lines) are shown. Beam energy for this patient was 18 MV.
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Figure 62: GTV DVHs for patient poses [01, 02 …] for patient 11. The planned dose is shown as the bolded black
solid line. For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses
(dashed lines) are shown. Beam energy for this patient was 18 MV.
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Figure 63: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient
11. The x-axes represent the dose difference in units of cGy. The numbers in the red/green boxes represent the
mean differences. For the D95 values, the average delivered dose is 57 cGy less than the average reconstructed
dose. Beam energy for this patient was 18 MV.
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Figure 64: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 12. The planned doses are
shown as the bolded black solid lines. For each simulated treatment fraction, both the delivered doses (thin solid
lines) and reconstructed doses (dashed lines) are shown. Beam energy for this patient was 18 MV.
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Figure 65: GTV DVHs for patient poses [01, 02 …] for patient 12. The planned dose is shown as the bolded black
solid line. For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses
(dashed lines) are shown. Beam energy for this patient was 18 MV.
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Figure 66: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient
12. The x-axes represent the dose difference in units of cGy. The numbers in the red/green boxes represent the
mean differences. For the D95 values, the average delivered dose is 70 cGy less than the average reconstructed
dose. Beam energy for this patient was 18 MV.
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Figure 67: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 13. The planned doses are
shown as the bolded black solid lines. For each simulated treatment fraction, both the delivered doses (thin solid
lines) and reconstructed doses (dashed lines) are shown. Beam energy for this patient was 18 MV.
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Figure 68: GTV DVHs for patient poses [01, 02 …] for patient 13. The planned dose is shown as the bolded black
solid line. For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses
(dashed lines) are shown. Beam energy for this patient was 18 MV.
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Figure 69: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient
13. The x-axes represent the dose difference in units of cGy. The numbers in the red/green boxes represent the
mean differences. For the D95 values, the average delivered dose is 137 cGy greater than the average reconstructed
dose. Beam energy for this patient was 18 MV.
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Figure 70: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 14. The planned doses are
shown as the bolded black solid lines. For each simulated treatment fraction, both the delivered doses (thin solid
lines) and reconstructed doses (dashed lines) are shown. Beam energy for this patient was 18 MV.
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Figure 71: GTV DVHs for patient poses [01, 02 …] for patient 14. The planned dose is shown as the bolded black
solid line. For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses
(dashed lines) are shown. Beam energy for this patient was 18 MV.
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Figure 72: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient
14. The x-axes represent the dose difference in units of cGy. The numbers in the red/green boxes represent the
mean differences. For the D95 values, the average delivered dose is 127 cGy greater than the average reconstructed
dose. Beam energy for this patient was 18 MV.
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Figure 73: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 16. The planned doses are
shown as the bolded black solid lines. For each simulated treatment fraction, both the delivered doses (thin solid
lines) and reconstructed doses (dashed lines) are shown. Beam energy for this patient was 6 MV.
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Figure 74: GTV DVHs for patient poses [01, 02 …] for patient 16. The planned dose is shown as the bolded black
solid line. For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses
(dashed lines) are shown. Beam energy for this patient was 6 MV.
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Figure 75: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient
16. The x-axes represent the dose difference in units of cGy. The numbers in the red/green boxes represent the
mean differences. For the D95 values, the average delivered dose is 5 cGy greater than the average reconstructed
dose. Beam energy for this patient was 6 MV.
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Figure 76: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 18. The planned doses are
shown as the bolded black solid lines. For each simulated treatment fraction, both the delivered doses (thin solid
lines) and reconstructed doses (dashed lines) are shown. Beam energy for this patient was 6 MV.
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Figure 77: GTV DVHs for patient poses [01, 02 …] for patient 18. The planned dose is shown as the bolded black
solid line. For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses
(dashed lines) are shown. Beam energy for this patient was 6 MV.
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Figure 78: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient
18. The x-axes represent the dose difference in units of cGy. The numbers in the red/green boxes represent the
mean differences. For the D95 values, the average delivered dose is 60 cGy greater than the average reconstructed
dose. Beam energy for this patient was 6 MV.

152

GTV

Rectum

Bladder

Figure 79: GTV, rectum, and bladder DVHs for patient poses [01, 02 …] for patient 19. The planned doses are
shown as the bolded black solid lines. For each simulated treatment fraction, both the delivered doses (thin solid
lines) and reconstructed doses (dashed lines) are shown. Beam energy for this patient was 18 MV.
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Figure 80: GTV DVHs for patient poses [01, 02 …] for patient 19. The planned dose is shown as the bolded black
solid line. For each simulated treatment fraction, both the delivered doses (thin solid lines) and reconstructed doses
(dashed lines) are shown. Beam energy for this patient was 18 MV.
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Figure 81: Histograms of the differences between planned, actual, and backprojected GTV dose indices for patient
19. The x-axes represent the dose difference in units of cGy. The numbers in the red/green boxes represent the
mean differences. For the D95 values, the average delivered dose is 3 cGy greater than the average reconstructed
dose. Beam energy for this patient was 18 MV.
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Figure 82: Distribution of bladder D25 deviations for each patient. Delivered versus planned deviations are shown by
the blue triangles. Backprojected versus planned deviations are shown by the purple x‘s. The mean deviations
between backprojected and delivered dose are shown by the orange circles.
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Figure 83: Distribution of bladder D50 deviations for each patient. Delivered versus planned deviations are shown by
the blue triangles. Backprojected versus planned deviations are shown by the purple x‘s. The mean deviations
between backprojected and delivered dose are shown by the orange circles.
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Figure 84: Distribution of rectum D17 deviations for each patient. Delivered versus planned deviations are shown by
the blue triangles. Backprojected versus planned deviations are shown by the purple x‘s. The mean deviations
between backprojected and delivered dose are shown by the orange circles.
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Figure 85: Distribution of rectum D35 deviations for each patient. Delivered versus planned deviations are shown by
the blue triangles. Backprojected versus planned deviations are shown by the purple x‘s. The mean deviations
between backprojected and delivered dose are shown by the orange circles.

159

Vita

Joseph Kingsley Gardner was born on October 15, 1979, in Atlanta, Georgia,
and is an American citizen. He graduated from Baylor High School, Chattanooga,
Tennessee in 1997. He received his Bachelor of Science in Physics from the University
of Richmond, Richmond, Virginia in 2001. He received his Master of Science in Applied
Physics from Virginia Commonwealth University in 2005.

Papers and Presentations:
Gordon, J. J., J. K. Gardner, S. Wang and J. V. Siebers (2012). "Reliable detection of
fluence anomalies in EPID-based IMRT pretreatment quality assurance using
pixel intensity deviations." Med Phys 39(8): 4959-4975.
Gardner, J. K., L. Clews, J. J. Gordon, S. Wang, P. B. Greer and J. V. Siebers (2009).
"Comparison of sources of exit fluence variation for IMRT." Phys Med Biol 54(19):
N451-458.
Wang, S., J. K. Gardner, J. J. Gordon, W. Li, L. Clews, P. B. Greer and J. V. Siebers
(2009). "Monte Carlo-based adaptive EPID dose kernel accounting for different
field size responses of imagers." Med Phys 36(8): 3582-3595.
―Acceptance Criteria for pretreatment QA EPID images‖. Talk given at AAPM
Mid-Atlantic Conference, 2008.
―Quantification of sources of fluence variation incident on an EPID‖ variation for
IMRT‖. Talk given at EPI2k8 conference, 2008.
Gardner, J., J. Siebers and I. Kawrakow (2007). "Dose calculation validation of Vmc++
for photon beams." Med Phys 34(5): 1809-1818.
Gardner, J. K., J. V. Siebers and I. Kawrakow (2007). "Comparison of two methods to
compute the absorbed dose to water for photon beams." Phys Med Biol 52(19):
N439-447.

160

